Other,neonatal
Investigation,Investigation
Resistance,shouldOvercomeBeforeClinicalApplication
Symptom,hyperglycemia
Immunohistochemistry,ELISA
Other,42Patients
Binding,key
Other,uniqueProperties
AMD3100,AMD3100
Comparisons,Comparisons
Other,antibody-anchoredMagneticBeads
Mastectomies,bilateralTotalMastectomies
Restoration,careProvider
Other,relationshipBetweenNlr
Subtype,subtype
Personalized,evenMorePersonalizedFollow-upSchedules
Intensity,smallProportion
Periods,periods
Odds,prevalenceOfobesityOf277Percecnt
Necessity,necessary
Other,importance
Other,importantTumor-promotingCells
Weight,patient'sTumorBurden
16,womenWithMore70PercecntOfPatientsTreatedWithHormonalTherapy
Proportion,neutrophil-to-lymphocyteRatio
Proliferation,secondaryConfirmationOfSignalAccumulationUsingNearInfraredFluorescentImaging
Paraneoplastic,likelyParaneoplastic
Restoration,restoration
Factors,incidenceFactors
Other,intracellularLevel
Other,total
Macrophages,tumor-associatedMacrophages
Apatinib,comparedBetween2GroupstheApatinib
Other,variousImportantFunctions
Other,consequentlyHaveDeveloped
Other,Disease
Other,positivelyAssociated
Utilized,mayUsed
Other,differentialDiagnosisInPatientsWithHistoryOfBreastSurgery
Description,molecularDiagnosisMethodMake
Subset,thanCapecitabineGroup
Other,broadDifferentialDiagnosis
Other,thriceHigher
Postmenopausal,relativeThoseOfPostmenopausalPatients
Cohort,public
Collision,impact
Global,womenInWorld
Other,haveDeveloped
Other,population-basedStudies
Other,assessedPreoperatively
Focus,cohortStudy
Result,ourPatient
Purpose,hormonalContraceptionUse
Water,course
Guidelines,internationalGuidelines
Circulating,circulatingTumorCells
Other,theirTissues
Other,driven
Mutations,Mutations
Evolve,age
Disease,cancer
Spread,cellInvasion
Switched,howeverSwitched
Actual,actualIncidence
Radiotherapy,evenSeveralChemotherapySessions
Other,4.71
Other,inBreastTumorsKnownAsBreastCscs
Other,pre-diagnosticObesity
Radiomics,radiomicsScore
Other,1984
Conflict,typeOfCollisionTumor
Subjective,personalGoals
Hazard,outcome
Other,groups
Costs,costs
Restoration,developmentOfGraphicallyTailoredScreeningTool
Adult,memorialSloanKettering-integratedMutationProfilingOfActionableCancerTargets
Circulating,circulatingSolubleRankl
16,mStage
Other,comparedToThoseWithPregestationalBreastCancer
Other,opticalCoherenceTomographyImages
Subgroup,generalPopulation
Other,tumorigenesisOfCells
Other,imperative
Interference,complication
Contribution,fearOfPartnerLoss
Intensity,lowClassificationAccuracies
Other,oneRandomlyAssignedToAxillaryDissection
Subtypes,differentiationBetweenBreastCancerInVariousSubtypesOfBreastCancer
Allele,tumorSuppressorFunction
16,16PrimaryBreastCancers
Finding,identificationOfPredictiveBiomarkersForSelectionOfOptimalTreatment
Other,Using
Disease,elevatedLesion
Other,obtained
Other,therapeuticSequencing
Other,level
Other,extensiveExploration
Preterm,mostPretermBirth
Other,affected
Other,uncommon
Hypomethylation,hypomethylation
Purpose,itsRole
Gene,geneExpressionLevel
16,secondDecadeAfterDiagnosis
Herceptin,neoadjuvantChemotherapyWithHerceptin
Other,descriptive
Other,opticalAbsorptions
Nano-genosensor,nano-genosensor
Other,13-hDailyOvernightFast
Contribution,inCaseReportTypicalOfAdvance
Focus,recentDanishCohortStudy
MiR-193b-3p,mir-193b-3pIdentifiedAsRegulator
Other,464Percecnt
Other,pool
Distinct,clearEvidenceForbenefitsOfTanUsageInBreastCancerClassification
Other,diverseBiologicalProcesses
Third-line,treatedWithCapecitabineMonotherapyAsThird-lineTherapy
CNN,shallowCnn
Positivity,diagnosisAccuracy
Decrease,harmToHealthAmongRuralWomenWithIncrementalCost-effectivenessRatio
Global,womenWorldwide
Gene,vascularAdhesionProtein-1
Testing,microscopicTestingOfHematoxylin
Other,them
Discovery,immunohistochemicalDetectionOfErPerformedInRoutineClinicalPractice
Cell,canDiagnosed
Testing,mammographicBreastCancerScreening
DSCAM-AS1,DSCAM-AS1
Caregiver,therapeuticAdvantagesParticularlyInCaseOfPremenopausalBreastCancers
160,160Patients
Other,backgroundTrastuzumab
Cell,canIncludedInDifferentialDiagnosisOfMasses
Other,MRI
Regimens,treatmentRegimens
Other,Information
Other,aimed
Reduced,smallMoleculeInhibitors
Distance,firstDiagnosis
Radiotherapy,anthracyclineChemotherapyAgents
Satisfied,satisfied
Other,SRC
Survival,synchrotronRadiation
Other,indicative
Kenya,breastCancerGeneticsInKenya
Other,proteinS-100
Testing,detectedThroughScreeningThroughSigns
Antibody,antibodyPanel
Mood,danger
Aspiration,fine-needleAspirationCytology
Benchmark,therapeuticTarget
Other,treatmentOfBreastCancer
Greater,greater
Cohort,youngWomenWithInvasiveLobularCarcinoma
Description,regressionModel
Reporter,dual-luciferaseReporterAssays
KDM4B,KDM4B
Originally,theirOriginallyTargetedPopulationsOfBreastCancer
Other,minimalRisksToNormalCells
Other,recentStudies
Other,emergingTechnology
Other,breastCancerRelapse
Other,veryHeterogeneousDisease
Other,treatmentProcesses
Other,resistant
Nonparticipation,clinicalFeasibilityOfCtcIsolation
Laser,carbonDioxideLaserTechnology
Other,show
Comparisons,comparisons10-yearSurvival
Testing,thematicAnalysis
Syndromes,diagnosisOfAcuteCoronarySyndromes
Other,relevant
Other,lessLikely
Learning,breastCancerClassification
Other,bone-modulatingAgents
MiRNA-21,eventHybridizationOfMirna-21Biomarker
Distinct,differentGeneticProfile
Interference,intervention
Testing,pathologyForFurtherFollow-up
Purpose,discrete-timePartiallyObservableMarkovDecisionProcess
Mood,complexTreatmentAlgorithms
Caregiver,mostPervasiveTypeOfCancerAmongWomen
Restoration,crucialImpactOnDevelopmentOfBreastCancer
Other,roles
Hybrid,hybridCultures
Other,inFluorescenceImaging
Other,mammographicImages
Signalling,eralphaSignalling
Gene,RANKL
Other,SP
Testing,riskFactorsOfLviByMultivariateAnalysis
Base,molecularBasis
Axillary,axillarySurgery
Other,time
Other,retrospective
Other,younger
Number,decrease
Amplification,positiveRegulatoryFeedbackLoopForFxyd3Amplification
Other,clinicalSetting
Other,recognizingMethylationStatus
Other,surgicalOutcomes
Race/color,associationBetweenRace/colorInWomenWithBreastCancer
Distance,interimStageInProgressionFromDcisToInvasiveBreastCancer
Disease,malignancies
Phosphorylation,phosphorylationOfAkt
Cell,canClassified
Heterogeneity,intratumoralHeterogeneityOfKindOfTumor
Distinct,cnvsOfDifferentCancers
Hazard,adjustedHazardRatio
Other,5Îœl
Hereditary,inheritableBi-objectiveCombinatorialGeneticAlgorithm
Estrogen-alone,estrogen-aloneArmOfWhi
Other,generallyReserved
Other,indispensable
Other,moreDirectional
Other,intensive
Parameters,intravoxelIncoherentMotionParameters
Other,repair
Other,processes
16,21Months
Other,proposedForBreastTumorGrading
Intensity,lowCtnLevels
Finding,antigenIdentification
Learning,extremeLearningMachineClassification
Other,respondents
Testing,screeningTools
Other,usefulness
Disease,autoimmuneDiseases
Regulatory,molecularRegulatoryNetworks
Nonparticipation,resistance
Other,significantlyHigherPcrRatesThanPatientsWithLuminalTypes
Considerable,largeBreastCancerTissueMicroarray
Network,networkOutput
1-2,isSentinelLymphNodesMetastasesTo1-2Nodes
Isolation,regressionModels
Exposure,highestPerformance
Other,accurateMethod
Other,accessToEarlyDiagnosis
Other,clinicians
Biopsy,tissueBiopsy
Somatic,esr1SomaticAlterations
Discovery,detection
Other,non-ideal
Other,including
Techniques,intelligentTechniques
Number,comparisonCohort
Other,hundreds
Hyperintense,irregularHyperintenseLesion
Survival,breastSurvival
Other,diagnosisOfBreastCancer
VAP-1,vap-1ImmunohistochemicalStaining
Bromide,breastCancerPatientsWithParticularReferenceToOverallSurvivalAndrecurrenceFreeSurvivalAmongBreastCancerPatients
16,13
Other,measures
Other,thoughtfulMultidisciplinaryPlanning
Chosen,fewStudies
Other,nationwideRegistries
Other,overallMediumSecondTumor-freeTime
Other,multimodalTherapy
Mortality,mortalityRates
Other,features
Necessity,mayNecessary
Provider,riskFactor
Other,recentEpigenomeStudies
Purpose,protectiveRoleOfRs5743810
Gene,PR
Resistance,theirApplication
Other,parameterUncertainty
Other,networks
Hazard,Risk
Other,higherRisks
Other,WES
Other,couldPotentialBiomarker
Overexpressing,her2Overexpressing
Restoration,standardOfCareAsFirst-lineTreatmentOfPatientsWithHer2-positiveAEvenInReal-worldSetting
Other,subsequentlyAssessed
Actual,currentUsersOfLongerDuration
Gene,TP53
Other,TRPV1
Other,breastCancerMcf-7
MABA,mabaSurgery
Other,2921Posts
Numerous,itInvolvesInManyCrucialMetabolicProcesses
Other,preclinicalPhase
Technique,noninvasiveImagingTechniqueForBreastCancerDiagnosis
Other,made
Factors,3ClinicopathologicalFactors
Mood,complexDueToPotentialFoetalRisksInSettingOfMaternalTreatment
Purpose,use
Other,designed
Other,forWomenWithBreastCancerMayMoreFeasible
Other,Japan
Interference,inCaseSecondaryToProximalBronchialObstruction
Will,betterUnderstanding
Required,needed
Other,Survival
16,sexualStigmatizationOfM
Collision,potentialImpact
Subgroup,standardizedDataCollection
16,50
Robust,strong
Chemical,DDT
Strategy,treatmentStrategy
Aspiration,aspirationCytology
Other,knockdown
Other,mainMeasures
Focus,prospectiveNestedCase-controlStudy
Conflict,leadingCauseOfDeathAmongGynecologicNeoplasias
Required,thereforeRequired
Output,lisbonRegion
Other,606Percecnt
Other,lesion
Other,advancesInBreastCancerDiagnosis
Other,whenonlyAnalyzed
Other,stageIi
Other,decreasesInMortalityRates
Discovery,timeIntervalsFromFirstDetectionToDiagnosis
Signature,intervalBetweenDiagnosis
Other,complexConsulting
Other,Results
Species,woman
Other,brca-associatedCancers
Other,pi3k/aktSignaling
Subgroup,population
Differentials,morphologicalDifferentials
Other,stage
CNN,CNN
Caregiver,descriptive-analyticCross-sectionalType160FemalePatientsWasselected
Apoptosis,impededApoptosis
Positivity,diagnosticAccuracy
Disease,amenorrhea
Considerable,large
Learning,dictionaryLearning
Focus,cross-sectionalStudy
Output,correctionMethod
Evolve,otherAgeGroups
Other,lymphedemaseventyPatients
Other,electricalDouble-layerCapacitors
DOX,cytotoxicityOfFreeDoxMolecules
Other,suspected
Water,alcoholConsumption
Benchmark,targetRelationshipBetweenDscam-as1
Positivity,99PercecntAccuracyInTermsOfClassification
Strategy,policyActions
Focus,non-sentinelLymphNode
Baseline,baselineSt-2Level
Monte,monteCarloFeatureSelection-basedFeatureSelection-basedComputationalMethod
Utilized,inPaperUsed
Predominant,predominant
Description,mainChallenge
Hazard,anticipatedOutcome
Disease,metastasis
Other,ourFindings
Other,taiwanLongitudinalHealthInsuranceDatabase2005
Image,image
Other,C1
Scans,chestCtScans
16,couldIndependentPrognosticBiomarkerForMPatients'Outcomes
Mutations,uniqueEsr1Mutations
Other,hasRecentlyProposedAsCrucialRegulatorOfTriple-negativeBreastCancer
Susceptibility,cancerSusceptibilityGenes
Ecchymosis,mrnaExpressionLevelOfPcdh10
Other,undifferentiatedNeoplasticCells
Ecchymosis,vap-1Expression
Disease,Metastasis
Hazard,non-standardLessPromptTreatmentsIrrespectiveOfComorbiditiesWithIncreasedRiskOfMortality/relapse
Other,lungCancerInHuman
Other,BMI
Other,Screening
MiR-511,thatOfMir-511
Image,energyImage
Solicitations,multipleSolicitations
Consensus,consensus
Other,ruralSetting
Care,healthcareUtilization
Amplification,inAdditionFurtherConfirmedInEarlyStage
Other,q12X
Ecchymosis,suutaneousEcchymosis
Other,tackled
Testing,treatingMedicalTeam
Other,severalObjectives
Other,means
Entry,information
Other,effectiveness
Debated,debated
Radiotherapy,palliativeChemotherapy
Will,understanding
Aptamer,aptamerMf3
Intensity,higherProportion
Other,72Months
Other,This
Other,Radiotherapy
Other,historyOfBreast-conservingSurgery
Solicitations,solicitations
Inverse,reverseTranscriptionQuantitativePolymeraseChainReaction
Number,hospitalCohort
CircRNAs,massiveCircrnas
Other,standardMethod
Pathogenic,pathogenicVariants
Discovery,microfluidicsBiomarkerDetection
Utilized,recentlyHaveUsedAsBiomarkers
Focus,axillaryLymphNodeOfBreastCancerPatients
Other,We
Cell,canImportantToDiagnosis
Other,concentrations
Hazard,shouldPerformedInAtRisk
Other,scrutinized
Purpose,mainObjective
Testing,advancedAnalysis
Network,bayesianNetworkMeta-analysis
Other,inexpensive
Other,specificGroups
Other,themselves
Strategy,multimodalityTreatmentStrategy
Other,summary
Other,twenty-twoPatients
Susceptibility,barcodeMode
Other,tendency
Other,drastic
Necessity,inConclusionStillNecessaryForAdoptionOfCtnAsRoutineClinicalBiomarkerInPatientsWithBreastCancer
Fibroblasts,cancerFibroblasts
Distinct,obtainedFrom66FemalePatientsWithMAtDifferentTimeIntervalsForEvaluationOfCtcsByFlowCytometry
Disease,triple-negativeBreastCancers
Adult,multiyearCollaborationLedByUnionForInternationalCancerControl
Alpha,p<
Other,inhibited
Adulthood,6084Years
AD,adPatients
Other,virtualRecombinedImagesFromLeImages
Conflict,differenceBetweenClearcellPlatformsForIsolatingCtcs
Cholecystectomy,Cholecystectomy
Alpha,P
Other,Porto
Other,mostCommonNeoplasms
Other,pregnancyOutcomes
Ecchymosis,expressionOfCxcChemokineReceptor-4
Cell,canUsed
Other,differentmethodsOfSelf-treatment
Obstetrician,shouldCo-managedByCardiologist
Filter,towaveletFilter
16,90PercecntOfPatientsWithRecurrence
Other,SD-CNN
Other,targetedTherapies
HER2-positive,confirmedUnilateralHer2-positiveBreastCancer
Testing,follow-upSchemes
Other,AUC
Other,aberrantlyExpressed
Other,solidTumors
Other,imagingModalities
Actual,currentResults
Testing,associationBetweenPreviousCervicalCancerScreeningInBreastCancerScreening
Parameters,quantitativeParameters
Distinct,timingOfChemotherapyForBreastCancersWithDifferentMolecularBackgrounds
Symptom,heavySymptomBurden
Other,Ki67
Purpose,mixedMethodsDesign
Other,fabricated
Advantage,interest
Conflict,toEndDevelopedWithDrugToAntibodyRatioOf329
Other,tangshanPeople
Other,theirParticularity
Other,additionalAnalyses
Other,immunohistochemicalTests
Other,practitionersKnowledgeable
Other,foxc1-knockdownBt549Cells
Provider,protectiveFactor
Other,timeInMostCountries
Other,dissection
Distinct,differentBreastCancerMolecularSubtypes
Other,mastectomiedPatients
Susceptibility,collectedFromElectronicHealthRecord
Intensity,highExpression
Other,humanBiofluid
Restoration,newOpportunitiesForDevelopmentOfNovelTherapeuticStrategies
Discovery,caDetection
Other,obtainedFromPatientsWithBreastCancer
Other,medianTime
Other,twoCases
Ecchymosis,stromalExpression
Technique,advantageOfHigh-throughputLuminexTechnique
Type,eighthEdition
Ecchymosis,dscam-as1Expression
Intensity,bodyMassIndex
16,120BreastCancerPatients
Other,Use
Lung/bronchus,lung/bronchusMalignancies
Other,figures
Other,8155Patients
Disease,dyspareunia
Bromide,-25-diphenyltetrazoliumBromideAssay
Other,ET
Other,problem
Other,133Controls
Benchmark,therapeuticTargetForPotentialTreatment
Actual,realNeedOfSurgicalTreatment
Intensity,unnecessaryFollow-upVisitsForWomenWithVeryLowRisks
Number,inConclusionPathogenicFeatureInPrimarySamples
Caregiver,type160Patients
Other,hasMade
Predominant,mostPrevalentType
Entry,additionalInformation
Other,advancedDiagnosticImaging
Other,third
Other,that
Coefficient,R
Other,down-regulatedInTissues
Elusive,themVeryDifficult
Care,attention
Other,LVI
Benchmark,patientsWithReducedBaselineLvef
Other,newSpecificMarkers
Other,intopreGroups
Subset,after6Months'TherapySignificantlyHigherIn3rdTertiaryGroup
Other,Therapies
Considerable,twoLargeBreastCancerDatabases
Other,multivariate
Evolve,significantlyYoungerAge
Other,adjuvantEndocrineHormonalTherapy
Number,increasingNumber
Other,accumulatingResults
Other,old
Other,56Patients
Provider,humanEpidermalGrowthFactorReceptor2ReceptorStatus
Other,featuresFromImages
16,10Mg/kg
Fertility,g1/s-phaseCellCycleArrest
Disease,malignancy
Other,standardMethodForEvaluationOfProposedPrognosticTumourMarkers
Other,positiveTreatment
Type,localizedDescription
Adulthood,35-64Years
Other,grade
Necessity,variableMolecularMechanismsOfCarcinogenesis
Originally,theirAbilityOfPrognosisPredictionInTheirOriginallyTargetedPopulationsOfBreastCancer
Other,microscopicImages
Testing,follow-up
Survival,threeOverallSurvival
Osteopontin,selectiveAccumulationOfFluorescentOsteopontinInVitroAndInVivo
Other,convolutionalNeuralNetworks
Other,700
Food,kernelApproach
Other,tumor-bearingMiceOfMcf-7BreastCancerCells
Disease,pleuralMetastasis
Other,occurringCancers
Other,ourBreastCancerPatients
Ecchymosis,prognosticMeritOfNek6ExpressionInBreastCancer
Cytology,surfaceMorphology
Susceptibility,generalHealth
Other,731Percecnt
Other,furthermoreAssociated
Other,malignant
Disease,tumours
Resistance,netvizzApplication
Other,effectsOfTreatment
Other,0.0001
Predominant,frequentMutations
Other,couldDetectedByMammographyBySelf-detection
Other,invasiveCarcinomaBreast
Disease,AD
Personalized,personalizedFollow-upSchemes
Mutations,esr1Mutations
Limitations,variousLimitationsIncludingToxicity
Other,involved
Other,women'sCancerAccounting
CLB-Pt-CLB,CLB-Pt-CLB
Associations,Associations
Interference,inWorkSynthesizedAsSystemForDeliveryOfDoxorubicinInTreatmentOfBreastCancer
Design,formulation
Parameters,parameters
Autoantibodies,autoantibodies
Other,conditions
Number,neonatalOfRetrospectiveCohortOfPregnantWomenWith
Other,drawbacks
Interference,multidisciplinaryAssessment
Other,established
16,12SampledWomen
Fibroblasts,fibroblastsAdjacent
Other,1973To2014
Positivity,betterDiagnosticAccuracyThanFfdm
Other,tightDoctor-patientCollaboration
Other,38Months
Demographics,Demographics
Sprays,ddtSprays
Filter,handheldProbeCapable
Hypomethylated,oftenHypomethylated
Other,shouldElaborated
Other,oestrogenReceptorCofactors
Testing,review
Other,0.46
Authors,authors
Interference,assessment
Other,she
Other,molecularAnalyses
NSAIDs,NSAIDs
Intensity,massInPosteriorFossaOfBrain
Gene,ESR1
Conflict,riskOfDeath
Gene,DESI-MSI
Number,presentedWorkForFeatureExtraction
Interference,theory-basedIntervention
Circulating,sixCirculatingMirnas
Cohort,youngMalePatients
Spouse,mutationalStatusBesidesFamilyHistory
Actual,effectiveDiagnosisOfBreastCancer
Other,childHealth
Evolve,evolve
Benchmark,impairedBaselineCardiacFunctionExperience
Other,treatment
Scalable,scalable
Other,radiationTherapy
Chemical,omega3FattyAcids
Other,sensitivityOf786PercecntRespectively
Long-term,inLongTermHasFound
Chosen,chosen
Purpose,broadUseToPatients
Kazakhstan,Kazakhstan
WHI,WHI
Guidelines,guidelines
Other,differentiallyExpressedInBreastCancerCells
Robust,robust
Other,responsibleMechanisms
Testing,testing
Phenotype,textureFeatures
Other,malignantProgressionOfBreastCancer
Other,resultsDiagnosed
Other,876PercecntRespectively
OS,betterOs
Mastectomies,mastectomies
Distinct,differenceBetweenDifferentBreastCancerSubtypes
MiRNAs,miRNAs
Late-stage,risksOfLate-stageDiagnosis
Other,analyzedBeforeAnd
Other,lobularCarcinoma
Vulnerability,vulnerability
Other,lipidProfiles
Troponins,troponins
Base,balb/cNudeMiceBearing
Cell,capacitance
TAMs,TAMs
Subset,subset
SE,highestSe
Other,added
Other,clinico-epidemiologicalFeaturesOfBreastCancer
Yoga,yoga
Understudied,understudied
Cell,Cell
Immunohistochemical,immunohistochemicalAnalysis
Other,DAU
Other,They
Other,suchStandardization
Other,tool
Other,18.791
Conflict,contrast
Restoration,postmenopausalWomenWithDevelopmentOfBreastCancer
Strategy,strategy
Gene,SOX9
Ecchymosis,proteinExpression
Other,insight
Adult,physicallyActive
Other,parpInhibitors
Other,patients'Self-monitoring
Macrophages,macrophages
MSOT,MSOT
Signature,signature
Subtype,oneSpecificSubtype
Other,interplay
Other,childbearingReasonsIncluding
V-G,v-gCalciumChannelBindingAntibodies
Other,observationalStudies
Other,pleuralDiseaseProgression
Proliferation,proliferation
Ecchymosis,ecchymosis
Japanese,Japanese
Fibroblasts,cancerAssociatedFibroblasts
Filter,probe
Other,eventualKnowledge
Other,pattern
Distinct,distinct
Prevention,prevention
Components,components
Other,furthermoreSignificantlyMoreLikely
Testing,ourTheoreticalAnalysis
Other,breastCancerTissueMicroarrayWithAccessToReceptorAnalyses
Adulthood,48Years
Other,couldDetectedEarly
Other,pH
Considerable,significantIncrease
PFS,significantlyProlongedMedianPfs
Anemia,Anemia
Other,5CmLess
Other,tomography
Number,base
Distinct,panelOfCellLinesWithDifferentPhenotypes
Symptom,firstSymptom
Other,typical
Discovery,label-freeDetection
Other,cancerTreatment
Noncoding,longNoncodingRnas
Other,dcisDiagnosis
Other,suutaneousLymphaticChannelsInReal-time
16,1000Patients
Postmenopausal,mainlyPostmenopausalWomen
Considerable,matchedHealthyTissues
Depletion,depletion
Contribution,contribution
Other,imagingIndexes
Symptom,symptomBurden
Complex,sialicAcidExpression
TBR,TBR
Mammographic,Mammographic
Distinct,risk/benefitOfDifferentTreatmentModalities
Vivo,evaluatedInVivo
Output,indicator
Number,foundInPcosCohortThanInComparisonCohort
Zt/g4-MMAE,Zt/g4-MMAE
Access,Access
Other,tumorNeoangiogenesisSimilarToBreastMagneticResonanceImaging
Gene,PALB2
Contribution,coverage
Other,better
Interference,interference
Other,oncogenesEsr1
Decision-making,personalDecision-making
Platform,microfluidicPlatform
Other,novelInsightsIntoPotentialMechanismsAssociatedWithBreastCancerPathogenesis
Other,advantages
Other,Univariate
Platform,platform
Other,diverse
SNVs,SNVs
TAAs,TAAs
Focus,case-controlAssociationStudyForVariantsInCodingRegionsOf11HereditaryBreastCancerGenesIn7051UnselectedBreastCancerPatientsOfJapaneseAncestry
Other,EMH
Other,dysregulation
Other,SUVmax
Water,fieldOfMedicalImagesDiagnosis
16,C
TAM,TAM
Focus,associationStudy
Mutations,esr1-activatingMutations
Kenya,Kenya
Cross-validation,cross-validation
MiR-204-5p,miR-204-5p
Of121,of121Patients
Activities,activities
Other,hasFound
Disease,neoplasms
Ecchymosis,proteinExpressionOfNf-krab-p65
PA,paTreatment
Distinct,differentPhenotypes
Predominant,inBelgiumMostFrequentWomen'sCancerAccountingForTo353PercecntOfCases
Other,hasAssociated
Caregiver,glycosylationOfMembraneTypeMr
Focus,focus
RNAs,RNAs
Purpose,contraceptionUse
RRM2,RRM2
Other,histologicGradeInBreastCancer
Cell,canImportant
Other,4Categories
Other,patientsWithNeoplasticDisease
MiRNAs,deregulatedMirnas
Disease,breastCancer
Restoration,closedLoopStructure
Other,x-rayMammography
Other,caloricRestriction
Other,experiences
Disease,inflammatoryTumour
Other,erEvaluation
Accumulation,abstractDataOnTheirClinicalCharacteristics
Other,furtherTissue
Nonparticipation,specificallyPlacedOnInflammatoryBreastCancerWithSkinInvolvementOnCutaneousMetastasesToBreastFromBreastCancer
Other,haveReportedInOnly003-06PercecntOfBreastCancers
Other,modified
Other,Familiarity
Subgroup,associationOfPcdh10Methylation
16,20
Ecchymosis,expressionProfileOfNek6In133BreastCancerSpecimens
Ecchymosis,extramedullaryHaematopoiesis
Focus,study
Other,481Women
Testing,comprehensiveResearchData
Intensity,improvedQualityOfLife
Percent,survivalRate
Focus,betterAccessToAtertiaryCancerCenter
Other,876Percecnt
Robust,strongAssociationBetweenRs5743810AgainstRiskInSaudiArabianWomen
Discovery,improvedDetection
Survival,survivalThanAdjuvantTherapy
Mood,agreement
Intensity,emphasis
Other,currentlyInsufficient
Axis,sparseCombinationOfRiemannianDictionaryAtoms
PFS,longerPfs
Protein-1,adhesionProtein-1
Radiomics,subsequentRadiomics
Other,the
Other,diagnosisOfPatientsWithBreastCancer
Other,patientsWithHistoryOfBreastSurgery
Other,haveDescribed
Susceptibility,health
Nucleus,posteriorFossaOfBrain
Platinum,twoChlorambucilPlatinum
Distinct,clinicalVariablesAmongDifferentGroups
Filter,nirProbe
Alpha,1H
Predominant,mostFrequentCancerInWomenTreatedWithHormonalTherapy
Other,57PercecntOfPatients
Prior,promisingShort-termStrategiesPriorToTreatmentAdministration
Neuromas,only35CasesOfTraumaticBreastNeuromas
Other,mammograms
Other,futureClinicalStudies
Disease,collisionTumor
Other,howeverWidelyUnderstood
Focus,experimentalStudyOfCryo-stabilityOfCancerCells
Users,12331Non-nsaidUsers
Subtype-specific,subtype-specificPrognosticSignatures
Mood,dryness
Other,stagingSystems
Disease,carcinogenesis
Testing,examination
Other,detectionofBreastCancer
Disease,obesity
Disturbances,sleepDisturbances
Other,analysed
Other,thusCritical
Distance,date
Other,method
Levels,levelsOfEralphaProtein
Other,haveCenterstage
Species,human
Other,1
Restoration,Development
Other,lower
Hazard,riskFactorsOfLvi
Restoration,panelOfMonoclonalAntibodiesAgainstNewlyEstablishedCellLine
Other,alreadyWell-established
Reduced,decreasedRiskOfBreastCancerInFemaleAdPatients
Other,explored
Matthews,matthewsCorrelationCoefficientOf8038Percecnt
Resistance,choiceOfChemotherapyInBrca-associatedCancers
Other,252Percecnt
Predominant,mostFrequentMalignancy
Restoration,developmentOfEffectiveDrugsForTreatmentOfHormone-dependentBreastCancer
Other,lungChanges
Other,opportunities
Entry,humanBody
Restoration,development
Other,transport
Other,westernBlot
Utilized,hasUsed
Other,obtainedFeatures
Other,Barshi
Other,multipleBiological
Restoration,furtherDevelopment
Subset,totalGroup
Other,progressionDisease
Other,higherRatesOfMisdiagnosisForBreastCancer
Linear,linearRegression
Subset,group
Other,breastTumorProgression
Other,haveClarified
Interference,barrierFunction
Subjective,existingEvidenceOnPersonalGoal-settingAmongWomenWithBreastCancerDiagnosis
Distinct,identificationOfDistinctiveGeneticModificationsInDifferentBreastCancerMolecularSubtypes
Other,oneRegionAnother
Other,therapy
Testing,willLeadToMortalityReductionsWithoutUsualScreeningHarms
Danger,nsaidExposure
Other,clinicalDepression
Alpha,S
Other,estrogen-receptorAmongOtherMarkers
Therapy-related,increasedRiskOfTherapy-relatedMorbidity
Other,patientsWithBreastCancer
Susceptibility,improvement
Obstetrician,generalRadiologistAboutSystemicDiseases
CNN,inception-v3Cnn
Pure,pureDcis
Other,available
Craniotomy,incompleteExcisionOfMalignantTissues
Discovery,breastCancerDetectionMethod
Other,alternativeMeans
Signature,response
PCOS,32620MatchedPatientsWithoutPcos
Other,shown
16,15Percecnt
Post,directEffects
Cell,canHeavilyInfluenced
Testing,breastCancerScreening
Testing,relatedResearchDataOfDiagnosisOfInoperableLocallyAdvancedBreastCancer
Immunohistochemistry,hasPutOnIntrinsicSubtypingBasedInPresenceOfClassicalImmunohistochemistry
Description,result
Other,Cells
Other,whereFacilitatedBySurfaceModificationOfNps
Other,markers
Other,CTCs
Testing,comparison
Other,spectrum
Disease,polycysticOvarySyndrome
Other,unmetPsychosocialNeeds
Discovery,finding
Bromide,bromideAssay
Subgroup,importantlyCouldPotentialDiagnosticBiomarkerInEthnicPopulation
Other,majorCscMarkersDescribedInInvasiveBreastCancer
Other,investigatedOnly
Locoregional,associationsOfFactorsWithLocoregionalAtDiagnosis
Interference,discovery
Other,thatOfOtherCountries
Other,carbohydrateRestriction
Other,comparedBetweenMetastaticSlns
Reporter,reporterAssays
Provider,secretionOfTumorNecrosisFactor
Other,alternativeOption
Purpose,newDesignDouble-layerCapacitors
Purpose,function
Nonparticipation,endocrineResistance
Evolve,medianAge
Subtype,triple-negativeSubtypeMda-mb-231Cells
Other,microRNAs
Other,largelyConsistent
Other,bilateralBreastLumps
Other,greatProgress
Conflict,associationsOfPhysicalActivityInGlobalHealthInBreastCancerSurvivors
Other,upregulated
Debated,oftenDebated
Adult,commonAdultCancers
Mechanism,termsOfMechanism
Other,inclined
Summaries,knowledgeSummaries
Description,picture
Focus,inPresentStudyPerformedFor9Features
Other,sensor
Radiotherapy,systemicChemotherapy
Other,manyBreastCancerPatients
Description,publicHealthChallenge
Arabian,saudiArabianWomen
Other,promoterMethylationInCertainTypesOfHumanTumors
Other,furthermoreMoreLikely
Species,patients
Testing,invasiveDiseaseretrospectiveAnalysisOf219Cases
Other,unknown
Conflict,issuesOfExistingContrastAgents
Other,sparseCoding
Other,sometimesMistaken
Locoregional,patientsWithLocoregionalInSouthernPortuguese
Other,Increase
Distinct,differentHistologicalAspects
Exposure,itsDiagnosticPerformance
Other,existence
Other,inverselyCorrelated
Cohort,poorAdhesion
Evolve,duringAgeAssociatedWithIncreaseOf8MoreFemaleBreastCancerCasesPer100000DuringAge50-54
Presentations,presentations
Benchmark,directTargetGene
Satisfied,moreSatisfiedWithTheirCosmeticResultsThanThose
Levels,post-nacBpeLevels
Gene,ERBB2
Other,properAccessToDiagnosis
Other,occurrenceOfBreastCarcinoma
Restoration,primaryCareProvider
Purpose,normalCardiacFunction
Symptom,symptom
Other,excision/lumpectomy
Other,recommendations
Will,releaseFromSerumStarvationInMcf-7Cells
Allele,tumorSuppressorFunctionOfP53InPathogenesisOfBreastCancer
Other,breastConservation
Craniotomy,surgicalExcisionWithRadiation
Cell,canConsidered
Food,patientEducationIdentification/reportingOfSideEffects
Evolve,possibleCorrelationsWithClinicalStatusIncludingAge
Base,advancedBreastCancerBearingMutationsInGenesInvolvedInPi3k/ark/mtorSignalingPathway
Other,physician
Japanese,7051UnselectedBreastCancerPatientsOfJapaneseAncestry
Young,femalePatients
Binding,binding
Care,analyzedtheOperationTime
Other,NMA
Lung/bronchus,subsequentLung/bronchusMalignancies
Entry,subsequentCancerCounselingOfFemaleSurvivors
Of121,totalOf121Patients
Learning,termsOfClassification
16,11BreastRadiologists
Disease,her2-positiveBreastCancer
Germline,244GermlinePathogenicVariants
Other,pathogenesisOfBreastCancer
Brain,brainMetastases
Other,gonadotropin
Cell,canEffectivelyTreatedByEndocrineTherapy
Other,thanDcis
Chemical,anastrozole
Accumulation,consistentMass-spectralData
Other,outcomesOfEstrogenReceptorPositive
Other,thereforeCriticalSignificance
Number,alarm
16,f-boxProtein22
Other,0.84
Testing,microscopicExamination
Survival,significantlyCorrelatedWithOverallSurvival
Specimen,sample
Levels,plasmaLevels
Other,haveProducedInLaboratories
16,subsequentMalignanciesForLung/bronchusCancerWith13PercecntSurvivorsSufferedFromSubsequentMalignancies
Conflict,evidencedByIncreaseInContrastAfterInjection
Other,noninvasive
Texture,textureAnalysis
Mechanism,potentialMechanism
Other,resonanceImaging
Other,Anthracyclines
Percent,percent
Other,accomplished
Mood,additionalLocalControl
Reduced,smallPopulation
Other,54BreastCancerPatients
Other,epidemiologicalFeatures
Other,singleMetastaticSite
Testing,medianFollow-upOf9Â·
Adult,mostCommonAdultCancersInKenya
Utilized,alsoUsed
Other,analyzedRetrospectively
Somatic,historyPhysicalExamFindings
Other,S+RT
Restoration,structureChanges
JAK-STAT,jak-statPathway
Proliferation,proliferationOfCells
Other,down-regulated
Focused,multivariateModelsAdjustedForIncome
Intensity,optimalCut-offValue
Food,foodRecommendations
Other,underutilized
Other,localTherapyOfBreastCancer
Other,shallow-CNN
Cytology,invasiveLobularHistology
Other,detected
16,120Patients
Other,yearRfsrate
Considerable,recognizedAsCtcIn1Of15HealthyBloodSamples
Other,147Patients
Nonparticipation,inConclusionStronglyAssociatedWithNonparticipationInS
Restoration,markerBands
Species,women
Young,femalePatientsWithAd
Interference,drugDeliveryStrategies
Other,1444Women
Mimics,twoCasesOfMimicsOfBoneMetastasis
Other,racialDisparity
Other,properties
Utilized,used
Testing,primaryPurposeOfPeriodicMammogramsInScreeningProgramsIs
Other,inPrimaryBreastCancerTumorsExpressedDuringNeoplasticTransformation
Focus,multicenterStudy
Random-sampling,random-samplingMethod
Disease,advancedBreastCancer
Nonparticipation,ctcIsolationTechniques
Intensity,lowDiagnosticSensitivityForWomenWithDenseBreasts
Isolation,penalizedLogisticRegression
Entry,cancerCounseling
Caregiver,roleOfPrimaryCaregiver
Accumulation,mainlyEurope
Entry,er-dependentTranscriptionalActivationViaTransactivationFunction1
Numerous,stillSeriousHealthProblemIn21stCenturySubjectToManyResearch
Finding,despiteTheirRarityShouldConsidered
Disease,carcinoma
Multi-stimuli-responsive,multi-stimuli-responsiveTheranosticNanoplatform
Other,Cases
Elusive,stillDifficult
Necessity,needForAnalysisOfMetastaticTissuesAtRecurrence
Other,rates
Platform,commonPlatformForStakeholdersIncludingPolicymakers
Other,positivelyCorrelated
Cohort,itsPoorPrognosis
Other,contextOfBreastCancer
Testing,cancerResearch
Other,haveReported
Learning,transferLearning
Other,future
Numerous,manyPatients
Other,understood
Other,breastMetastases
Testing,research
Utilized,haveUsed
Gene,BRCA1/2
Values,optimalCutoffValues
Focused,hasFocusedOnTumourCellsPrimarily
Other,screened
Oxidation,greaterthanorequaltoReduction
Other,downregulated
Entry,counseling
16,detectedByImmunohistochemistryInApproximately70PercecntOfInvasiveBreastCancers
Ecchymosis,expression
Subgroup,onlySubgroupWithProgesteroneReceptor
Susceptibility,whenIntegratedWithinCountry/region'sHealthPlan
Other,determine
Regimens,shorterRadiotherapyRegimens
Spouse,femaleSibling
Stigmatization,mostStigmatization
Levels,ctnLevels
Actual,currentAnalysis
Hazard,increasedRisk
Provider,tumorNecrosisFactor
Pure,pureDcisInClinicopathologicCharacteristics
Other,patientsWithMeasurementErrors
Other,Recurrences
Other,breastCancerPatients
Other,otherInotherTertiaryCentres
Other,couldDetected
Disease,heterogeneousDisease
Distinct,differentDetectionRates
Reduced,decreasedGrowth
Other,casesWithoutMetastasisOnDiagnosticImaging
Other,preoperativeCytologicalDiagnosisOfBreastCancerMetastasesInRegionalLymphNodesIn84Patients
Testing,linerRegressionAnalysis
Other,tools
Pure,moreAggressiveBiologicalNatureThanPureDcis
Other,feasible
Restoration,widelyAcceptedAsStandardOfCareFollowingBreastConservation
Disease,fanconiAnemia
Mood,veryComplexDisease
Distinct,differentDetectionRatesInBreastCancerPatients
Other,howeverHaveClarified
Mood,controlGroup
Hazard,hazardRates
Other,4Domains
Other,0.00001
Greaterfor,howeverGreaterforPatientsTreatedInAlmatyCity
Distinct,willDifferent
Disease,paraneoplasticNeurologicSyndromes
Other,delaysinTreatment
Provider,riskFactorForLung/bronchusCancer
Intensity,outcomeInEr-positive/humanEpidermalGrowthFactorReceptorType2-negativeBreastCancersWithHighHazardRatiosIndependentlyOfOtherMarkers
Considerable,largeCells
Distinct,ourPreviousWorkRegardingToPropertiesOfPluronicsWithDifferentPhotosensitizerForPhotodynamicTherapy
Survival,overallMedianSurvival
Nonparticipation,nippleInvolvement
Ecchymosis,preservationOfBiomarkerExpressionInOldFfpeTumour
Other,conducted
Symptom,novelStrategiesForDiagnosisOfBreastCancerWithHyperglycemia
Other,benignBreastLesions
Cohort,peripheralBlood
Necessity,immediateUnmetNeed
Water,essentialRole
Other,breastCancerSubtypesa
Other,prospectiveStudies
Robust,weakToStrongReactivityToOtherCellLines
Other,MP
Hereditary,distinctiveGeneticModifications
Other,67BreastCancerSamplesFrom66Patients
Testing,breastCancerScreeningProgramme
Other,gynaecologicalMetastases
Other,mayIndicativeOfBenignLesion
Other,neutralEffects
Other,mostWomen
Alpha,m
Other,earlyStage
Other,alarmingLevelGlobally
16,23Studies
Chemical,estrogen
Other,overexpressed
Other,recentlyDiagnosedBreastCancer
Disease,AION
Other,oedema
Other,patterns
Ecchymosis,decreasedExpression
Evolve,medianDiagnosisAge
Disease,tumor
Young,malePatients
Other,urgentClinicalProblem
Other,common
Other,improvedCancerTreatment
Other,avoidance
Other,scope
Other,inflammatoryDiseases
Cross-validation,tenfoldCross-validationMatthew
Testing,patient'sMedicalHistory
Other,included
ST-2,st-2Level
Supplements,supplements
Robust,robustTechnology
Other,luminalB-likePatients
Other,likely
Necessity,mustAddressedDuringCancerGeneticCounselingConsultations
Other,breastCancerTherapy
Focus,amongThemNewlyIdentifiedInStudy
Other,breastCancerCells
PCOS,effectsOfPcosOnRisksOfGynecologicCancer
Other,premenopausalPatients
Other,whenSuspected
Capillaries,bareCapillaries
Cell,canDifficult
Other,Factors
Other,appropriateDiagnosisOfBreastCancer
Other,developed
Strategy,system
Other,moreAdvancedStages
Other,992Percecnt
Women,conclusionsWomen
Other,report
Hazard,worseOutcome
Contribution,bestAvailableEvidence
Other,thepresence
Other,Analysis
Other,real-time
Filter,similarTowaveletFilter
Other,icgFluorescenceMethod
Interference,preoperativeAssessment
Other,68Percecnt
Testing,breastExamination
Other,ruralCancerHospital
Young,female
Benchmark,promisingTherapeuticTargetForBreastCancer
Other,comparedBetweenPremenopausalGroupsBetweenPcrGroups
STs,stsOfDeath/relapse
16,90Percecnt
Focus,resultsOfStudy
Adulthood,years
Entry,initiationOfPromptTherapy
Other,408
Food,experience
Obstetricians,obstetricians
Adverse,similarSeriousAdverseEvents
Other,505Percecnt
Focus,sentinelNodeBiopsy
Testing,oneScreeningProgramme
Hybrid,neuralNetworkClassifier
16,10Percecnt
Other,bio-metal-organicFrameworkCoated
Other,allBreastCancerPatients
Targeted,novelTargetedTherapeuticOptions
Long-term,theirLong-termSurvival
Comparisons,comparisons
Ecchymosis,relationshipBetweenStromalExpressionOfPodoplaninInInvasiveBreastCarcinoma
Other,history
Ecchymosis,patientsWithHer-2PositiveExpression
Other,Chi
European,europeanCountries
Township,country
Required,urgentlyNeeded
Other,hormone-dependentPositiveBreastCancer
MORC4,morc4Silencing
16,50PercecntRelapsedTissues
Interval,period
Delays,higherRisksOfTreatmentDelays
Decrease,increase
Other,manyFeatures
Mood,complexSurgeries
Other,417Percecnt
Interference,newerDrugDeliveryStrategies
Other,mostRelevantKind
Other,keys
STs,STs
Other,disease
Reduced,decreased
Cell,cellProliferation
HER2,patientsWithHer2
Correlation,correlation
Other,significanceOfTime-trends
Binding,stableDrug-carrierBinding
Subset,preliminaryGroupOfCtibl
Other,prognosticSignificanceOfNlrInEarlyStage
Trastuzumab,trastuzumab
Benchmark,potentialTarget
Learning,deepLearning
Disease,pretermBirth
Restoration,goodDiagnosticAbility
Other,occurring
Other,advancedStage
Binding,selectiveBinding
10-fold,10-foldCross-validation
Alpha,moreComorbiditiesThanSPatients
Other,4
Purpose,roleOfPdgf-b/pdgfr-betaAxisInRareTypesOfBreastCancers
Other,fusionProteinsWithHaloTag
Discovery,incidentalFinding
Antibody,paraneoplasticAntibodyPanel
Other,alsoAssessedByQrt-pcr
Other,howeverUnderutilized
Testing,analysis
Other,improved
Spouses,Spouses
Other,hypothesis
Decrease,inTotalMatchedToCasesOnBirthYear
Other,attempted
Other,leucocytes
Disease,metastaticBreastCancer
Other,megakaryocytes
Other,risks
Its,itsExpressionLevel
16,G
PCOS,pcosGroups
Other,evaluation
Parameters,pharmacokineticParameters
Restoration,article
Other,overexpression
Genes,genes
Purpose,long-termUse
Other,access
Percent,mortalityRate
Other,vital
Other,xenograftMice
Strategy,screeningStrategy
Other,virtualReality
Other,benign
Desirable,moreDesirable
Disease,DCIS
Filter,novelNear-infraredNirFluorescentProbe
Other,applied
Other,employed
Other,majority
Other,novelMethod
Other,importantInsightsIntoDiagnosisOfPatientsWithDisease
Spread,lymphaticInvasion
Distinct,definedSubtype
Gene,NCAM1
Other,correlated
Personal,theirOwnParticularity
CLB-Pt-CLB,clb-pt-clbProdrug
Other,patientsByTrastuzumab-pretreatment
Benchmark,canTherapeuticTargetForNextGenerationOfSerms
Testing,ourLiteratureReview
Cell,cancerStemCellHypothesis
Discovery,determinationOfUnderlyingBiologyWithinTumors
Adulthood,476Years
Evolve,youngerAge
Hazard,risk
Distinct,differentSubtype
Other,segmentationAlgorithm
Other,tissue
Intensity,adjustedProportion
Output,indicatorOfNacEffectiveness
Conflict,activity
Testing,histopathologicalExamination
16,13PercecntOfDeaths
Distinct,hasAlreadyAssociatedWithDifferentCancersNon-hodgkin'sLymphoma
Other,diagnoses
Other,decreases
Other,adherence
PFS,similarPfs
Image,enhancementOfImage
Other,preoperativeDiagnosis
Cohort,theirExperiencesLivingWithSister
Hazard,highestRisk
Restoration,developmentOfBreastCancer
Other,stronglyPositive
Estrogen,estrogenReceptor-alpha
Spouse,familyImpact
Purpose,increasedRiskWithUseOfLevonorgestrelIntrauterineSystem-bothOfPotentiallyImportantFindings
Advantage,widespreadInterest
Mutations,twentyUniqueEsr1Mutations
Caregiver,73-yearOldWomanPresentingWithLeftBreastLumpClinicallyIndeterminate
16,11HereditaryBreastCancerGenes
Susceptibility,changesInHealthBehavioursAfterBreastCancerDiagnosis
Other,evidence-basedRecommendations
Intensity,lowCountries
Other,stillObscure
Considerable,significantChallenge
LVEF,negativelyCorrelatedWithLvef
Other,earlyBreastCancerSurgery
Other,CGI
Intensity,influenceOfSleepQualityOnPmInPatientsTreatedWithHt
Signature,three-lncrnaSignature
Other,shouldPerformed
Strategy,short-termStrategy
Other,prohibitivelyExpensive
Other,haveReportedMainlyAfterMastectomy
Fertility,importanceOfProactivelyAddressingFertility
Description,treatmentOutcomePrediction
Other,BRCAs
Other,65Patients
Weight,tumorBurden
Advantage,handicap
Intensity,amount
Exposure,equivalentPerformance
Other,sentinelNodes
Other,year
Other,heterogeneous
16,betterUnderstandingOfRisksAssociatedWithM
Finding,growthOfFbxo22-depletedEr-positiveBreastCancers
Mood,surgicalOptionsIncludingPreservationOfNippleAreolaComplex
Adult,february2012InNargisDuttMemorialCancerHospital
Global,world
Other,MCC
Ecchymosis,nek6Expression
Disease,triple-negativeBreastCancer
Other,differentiation
Testing,scan
Other,clinicalBreastCancerTrials
Other,negativeEffects
Intensity,lowLevel
SNVs,sharedSnvs
Other,hasReported
Expert,bulkyHighlyTechnical
Other,5-khzFrequencies
Trastuzumab,trastuzumabTherapy
Conjugate,clinicalBreastExaminationCoupledAsPrimaryTool
Other,0.520
Distinct,defined
Other,clinicopathologicalCriteria
Amplification,signalAmplificationStrategies
Finding,identification
Symptom,effectOfDdtSpraysOnBreastCancerIncidenceRate
Utilized,currentUtilizedHistopathologicBiomarkers
Conflict,cancerDeathAmongWomenWorldwide
Relative,relativeThose
Susceptibility,healthCenters
Focus,ourStudy
Evolve,ageOfTreatmentMethods
Other,z-test
Other,howeverKnown
Testing,byWhichObservedInNondestructiveWayThroughThermalAnalysis
Cox,coxHazardRegressionModels
Other,obscure
Other,standard
Disease,metastaticDisease
Values,cutoffValues
Proportion,ratio
Interference,evenLessFrequentComplication
Distance,firstFiveFacebookOpenBreastCancerGroupsInYear2016
Other,planning
Levels,bpeLevels
Other,metastasectomy
Other,182Percecnt
European,9EuropeanCountries
Other,staining
Other,rituximab
Ecchymosis,expressionInBreastCancer
Subtypes,breastCancerMolecularSubtypes
Purpose,associationBetweenPost-diagnosisUseOfLow-doseAspirin
Other,inNearFutureContribute
Distance,characteristicsInsideTumors
Other,an
Testing,screeningPrograms
Other,Identification
Fibroblasts,fibroblasts
Mutation,rs5743810
Distinct,differentLong-termSurvival
Disease,ductalCarcinoma
Other,clinicalSettingOfPreviouslyVagueDiagnosisInImaging
Other,framework
Contribution,inMarch2014BroadcastedAsPart
Ecchymosis,expressionOfMir-511InBreastCancer
Danger,ddtExposure
Mood,thusInRecentYearsDemand
Other,anti-apoptoticEffectsOfEstradiol
Finding,automaticIntraoperativeIdentificationOfBreastCancerMargins
Other,over-represented
Considerable,substantialImprovements
Other,responsible
16,womenWithG
Other,adherenceToEhtAmongBreastCancerPatients
Gene,VAP-1
Other,leastAbsoluteShrinkage
Township,thenLinkedToTownshipFemaleBreastCancerIncidenceRateIn2000s
Other,precision
Other,timeOfTheirAppointmentwithDoctor
Other,Isolation
Other,significantlyAssociated
Lung/bronchus,incidenceFactorsOfSubsequentLung/bronchusPrimaries
Cell,cellMigration
Other,understand
Other,greatPotentialInDiagnosisTherapyOfCancers
Will,furtherUnderstanding
Other,prognostic
Survivors,youngerBreastCancerSurvivors
Description,asResultAreUsed
Other,urgentlyDeveloped
Other,er-positiveBreastCancer
Other,hugeVolumes
16,510YearsAfterSurgery
Disease,RDD
Discovery,moreResearchLight
Other,FT
Other,mostCommonMalignantTumor
Other,Mammography
Disease,breastCancerWisconsin
Other,defectStudies
Alpha,p
Other,mda-mb-231Cells
Testing,standardBiomarkerTestingByImmunohistochemistry
Other,us
Other,postoperativeComplications
Interference,chronicDebilitatingLifelongComplication
Township,accurateViewOfStateOfMetastasesToAxillaryLymphNodes
Purpose,methodsDesign
Conflict,contrastAgents
Subset,sameRangeAsCasesWithoutWavelength-dependentMeasurementErrors
Provider,factor
Discovery,detectionMethod
Finding,tumorGrowthInExperimentalModels
Other,noninvasiveImaging
Other,magneticResonanceImaging
Other,otherDietaryRecommendations
Protocols,protocols
Benchmark,thusPotentialTherapeuticTarget
Mimics,needForAwarenessOfMimicsOfBoneMetastasis
Other,localTherapy
Other,howeverMuchLower
Contribution,theyCanImpactOnQualityOfLifePresent
BPE,BPE
Other,1Year
Pearson,pearson'sR
Steps,Steps
Accumulation,lowerInEasternThanNorthern/centralEurope
Focus,sentinelLymphNode
Contribution,5-yearResultsOfPhase3Isg23-01Trial
Other,associated
Purpose,willTestedThroughEuropeanMyPersonalBreastScreening
Nondestructive,mostNondestructiveTests
Other,times
Other,approximately75PercecntOfBreastCancers
Intensity,massSpectrometry
Amplification,addition
Other,uncover
Formed,formedByCo-encapsulationOfNear-infraredFluorophoreInPegylatedMicelles
Other,alternativeToFrozenSections
Testing,lastFollow-upTime
Adulthood,breastCancerYoungerThan45Years
Other,commonCancerTypes
Symptom,evidence
Fertility,flowCytometry
Filter,osteopontin-basedProbe
Actual,highlyEffective
Other,spindleCells
Other,we
Coefficient,correlationCoefficient
Other,clinicalPractice
Other,theirParaffin-embeddedTissues
Water,water
Other,potentialBiomarkerForCancerDiagnosisThanMrnaBiomarkers
Number,numberVariants
Other,influences
Other,proposed
Other,Stem-likeCells
Other,only44Percecnt
Other,twoUncommonCasesOfDelayedBreastCancerRelapses
Other,life-threatening
Number,automatedAnalysisOfClinicallyRelevantHistopathologicFeature
Output,stat1RecruitmentToEralphaPromoterRegion
Other,haveAssociated
Global,heterogeneousCancerInFemalePatientsWorldwide
Focused,hasFocused
Pleurodesis,pleurodesis
Other,mostCommonCancer
Positivity,theirAbility
Radiomics,radiomics
Young,performedInFemaleParticipantsWithBreastCancerFromJune2015ToDecember2017
Cohort,moreoverPoor
CS/Bio-MOF,doxUptakeByCs/bio-mof
Other,this
93,forThoseWithNormalLvef93Percecnt
Other,operablePatients
Other,disadvantages
Interference,tripleAssessmentFollowed
Restoration,goodTolerabilitytheApatinib
Other,chronic
Disease,maleBreastCancer
Other,sequencing
Restoration,clinicalCare
Result,threeCtcsIsolatedFromOnePatient
Focus,mammaryMetastasisFromCarcinomaOfOvarianOrigin
Spread,progressionOfTumorInvasionInBreastCarcinoma
HER2,phForHer2AgainstHer2-overexpressedBreastCancer
Other,clinicalOutcomesDiffer
Focus,retrospectiveObservationalStudyOf264Her2-positiveAdvancedBreastCancer
Considerable,significant
Subtypes,otherSubtypesOfBreastCancer
Other,variousRadiologicalChangesLeadingToDiagnosticChallenges
Restoration,rural-basedTertiaryCancerCareCenter
Other,approaches
MiR-34s,miR-34s
Other,breastCancerCases
Description,finalMultipleRegressionModel
Acids,omegaFattyAcids
Other,chances
Other,expressedSeparately
Contribution,bestStandardTreatmentRegimenAvailable
Entry,itsHistologicAppearance
Other,epigeneticAberrations
Other,mortality
Alpha,comorbiditiesThanSPatients
Other,643Percecnt
Regimens,chemotherapyRegimens
Other,ORR
Other,Follow-up
Description,characterization
Other,higher-qualityImaging
Susceptibility,theirHealthBehaviours
Other,normalTissues
Quantification,feasibleInProperlySelectedCasesWithAsymptomaticNeuromasAfterAccurateTissueSampling
Other,context
Actual,potentialOfAionAsEffectiveMultimodalContrastAgentForBreastCancerDiagnosis
Other,proposedMethod
Quantification,successfulQuantificationOfCa15-3InSerumSamplesFromCancerPatients
Other,pCR
Scalable,scalableIntervention
VAP-1,vap-1StainingResults
Accumulation,otherData
Other,breastCancerGrading
Purpose,roleOfEstrogens
Mood,breastCancerControl
Other,cross-sectionalCategories
Subtypes,canCategorizedIntoSubtypesOfLuminalA
Other,high-resolutionImages
Other,challengingProblem
Ecchymosis,expressionOfRrm2
Subgroup,associationBetweenTumorUptakeInInvasiveDuctalCarcinoma
Other,one-waySensitivityAnalyses
Utilized,mostCommonAgentsUsedInBreastCancerTreatment
Contribution,bestChancesOfCure
Provider,independentPrognosticFactorForDfsOfEarlyStageBreastCancer
Other,hasMadeInMolecularSubtypingOfBreastCancer
Other,large-scaleStudies
Other,performedFromInceptionToJanuary312018
Other,SpCM
Food,assay
Formed,alsoShaped
Disease,Tumours
Other,statisticalClassifiers
Comparisons,cytohistologicalComparisons
Bromide,reference
Other,support
Other,7581StageI/iiaCases
Membrane,panel
Chemical,DDE
Interference,withBetterDrugDeliveryPotentialOfNon-sphericalShapesHaveRecentlyInvestigated
Finding,tumorGrowth
Other,represented
Other,patientsWithBreastCancerReceivingWithAnthracyclines
Other,cancer-relatedDeathsAmongWomen
16,only20Percecnt
Entry,moreInformationAboutFurtherStratificationOfBreastCancerSubtypes
Other,ICER
Poisson,zero-inflatedPoissonRegression
Chemical,baicalin
Other,breastCancerModels
Global,firstOrganisedRound
ST-2,3GroupsBasedOnTertiarySolubleSt-2Level
Restoration,neededAcrossCareContinuumEspeciallyInLow-resourceSettings
Systematic,inCanadaOfferedInOrganizedPrograms
Other,accessToReceptorAnalysesInCytosolAtDiagnosis
Other,measurements
Other,alteredInHumanBreastCarcinoma
Other,confirmed
Focus,study'sObjectives
Other,diseases
Signature,medianInterval
Purpose,criticalRole
Genes,breastCancerGenes
Restoration,standardOfCareForBreastCancer
Cohort,fastingBlood
Intensity,highAmountOfDox
Other,localExcision/lumpectomy
DNA,dnaMethylationDifferencesBetweenTumorBreastTissue
Subgroup,subgroupVariables
Intensity,lowRiskLesions
Parameters,similarExperimentalParameters
Other,pcrResults
Description,higherResolution
Cell,CellLines
Positivity,receiverOperatingCharacteristic
Targets,novelTherapeuticTargetsFor
Other,remarkableImprovements
Other,moreAdvancedStagingAtDiagnosisInWomen
Distinct,diseaseDefinedByTumor
Disease,overallSurvival
Other,occultBreastTumors
Symptom,evidenceForbenefits
SPD,proposedCovariance-basedSpdMatrices
Testing,forefrontOfResearch
Interference,interventionArm
Other,significantlyHigher
Image,correspondingHistologyImage
Factors,protectiveFactors
Other,therapies
Prior,priorMedicalHistory
Other,robustSynthesisMethods
Specimen,only1ulOfSerumSample
Other,dependent
Entry,variousOtherCancerInHumanBody
Cell,canStarted
Intensity,high
Conflict,atEndOfFollow-upClassifiedRegardingTheirAdherenceToRecommendationsForCancerPrevention
Conflict,followedFromDateOfFirstDiagnosisOfAdToEndOf2013
16,12EventsAmong121Patients
Other,first-lineTreatment
Actual,currentMeans
Other,grafts
Subset,meanwhileBetterThanInCapecitabineGroup
Other,observations
Other,inconsistentResults
Other,mastectomizedWomen
Other,breastCancerIncidence
Considerable,substantialDiscordancesBetweenPrimaryTumors
Other,humanChorionicGonadotropin
Paraneoplastic,mostLikelyParaneoplastic
Hybrid,pD1542yMissenseMutation
Odds,correlationsBetweenOdds
Purpose,objective
Restoration,conflictBetweenCareOfMother
Other,arms
Other,macrophage-targetedTreatmentStrategies
Restoration,publicHealthCareSystem
Basis,inConclusionDownregulatedInBreastCancer
Positivity,accuracy
Other,breastMetastasis
Other,perturbation
Other,thereforeAdministered
Subgroup,statisticalAssociation
VAP-1,vap-1Staining
Necessity,mustAddressed
Conflict,cellCycleArrestFollowedByMassiveCellDeath
Interference,postAssessment
Testing,screeningBehavior
Herceptin,Herceptin
Other,they
Other,Israel
Other,analyzed
Intensity,highSensitivity
CircRNAs,circRNAs
Purpose,role
Other,preclinicalModels
Presentations,rarePresentations
Other,earlyBreastCancer
Situations,needForNodalRadiotherapyInSpecificSituations
Survival,survival
Aberrances,aberrances
Cytology,histology
Other,images
MSOT,msotImaging
Odds,noticeableDrugLoadingCapacity
Factors,factors
9398,9398
Levels,expressionLevels
Focus,rightMastectomyWithSentinelLymphNodeBiopsy
Other,previousStudies
Fertility,variousCellularProcessesCellCycleRegulation
Other,cruciferousVegetables
Adulthood,0-5Years
Other,symptomaticWomen
Other,infiltrationSimilar
Other,exercise
Other,healthInitiative
Focus,includedInStudy
Nek6,Nek6
Other,negativeMargins
Other,relationship
Subtyped,subtyped
Lymphedema,secondaryLymphedema
Other,505PercecntOfAnalyzedCases
Other,highlyExpressed
Formed,shaped
Craniotomy,craniotomy
Radiotherapy,neoadjuvantChemotherapyGroups
Levels,levels
Restoration,immunocaptureOfMarker
Mastectomies,bilateralMastectomies
Other,highestIncidenceAmongMalignanciesDiagnosedInWomen
Adulthood,2-3Years
Other,haveDiscovered
Mood,nippleAreolaComplexInvolvement
Adulthood,1YearTo5Years
T2,T2
Number,number
Disease,chorea
Cohort,ctcsFromPeripheralBlood
CMIA,CMIA
Global,worldwide
SE,SE
Food,specificFoodRecommendations
Other,mistaken
Correlation,expectedInverseCorrelation
Radiotherapy,practicalImplicationsOfOngoingChemotherapy
Predictors,predictors
Platform,areaUnderReceiverOperatingCharacteristicCurve
RON,ronReceptorTyrosineKinase
Evolve,ageGroups
Disease,death
Bayes,reportOnPerformanceOfBayesClassifiersLikeTreeAugmentedNaiveBayes
Other,methylationStatus
Other,interpretation
77,77
Image,imageSegmentation
Conflict,collisionTumorWithBreastCancerMetastasis
Other,expected
Spouse,familyHistoryOfDisease
Other,humanErrors
Disease,heartFailure
Biopsy,biopsy
Binding,denosumabInjection
Utilized,widelyUtilized
Other,weak
Other,portugueseInstitute
Other,retrieved
Genes,severalOtherGenes
Other,905Percecnt
Testing,search
Alpha,r
Distinct,threeDifferentClusters
Conflict,conflict
Nonparticipation,nonparticipation
RL,appliedTo70PatientsWithUnilateralRl
Ecchymosis,rrm2Expression
Other,menopausalHormoneTherapy
Capabilities,capabilities
Values,values
Other,reality
Discovery,multiplexedAssayForDetectionOfAutoantibodiesInCanineTumours
Other,pathogenic
Other,CXCR4
Restoration,developmentOfPolicies
ERalpha,eralphaTranscription
Adulthood,62Years
AYAs,AYAs
Filter,ultrasound-guidedDiffuseOpticalTomography
Other,non-coverage
Late-stage,late-stage
Subgroup,association
Gene,HER2
Biocharacter,biocharacter
Technique,imagingTechnique
Intrapulmonary,newBilateralIntrapulmonaryNodules
Will,releaseProfile
Quantification,quantification
Understudied,understudiedPattern
Danger,nsaidsExposure
Subgroup,patternsOfAssociationResults
Other,twoGroups
Positivity,accuracyScores
Other,complementaryApproaches
Utilized,utilized
MiR-511,mir-511Overexpression
Other,haveObserved
RL,RL
Subtypes,subtypes
Restoration,mustIndividualizedWithEmphasisOnOptimalCareOfMother
Testing,autopsyStudies
Odds,odds
Differentials,differentials
SPD,spdMatrices
Entry,bodyWeight
Restoration,cancerCareCenter
Advantage,tumorSizethePositivity
16,mPatients
Validation,Validation
Chemical,estrogens
Spread,tumourSpread
Other,disseminatedDisease
Learning,ronInternalization
Other,inHumanBreastCancerHasReported
Resistance,potentialApplicationForDiagnosisOfCancerInFuture
Mood,activatedComplex
Technique,technique
Water,fieldOfBreastCancerDetection
Cell,cell
Scientific,criticalScientificBase
16,100000Person-years
Co-existence,Co-existence
Biocharacter,agonistic/antagonisticBiocharacter
CEDM,CEDM
Other,commonComplaint
Other,suchSymptoms
Other,experts
Other,occurrence
Other,shouldStaged
Other,cancerDiagnosis
Aptamer,ssdnaAptamerMf3
Evolve,inConclusionMajorHereditaryBreastCancerGenesIrrespectiveOfAgeAtDiagnosisInJapaneseWomen
European,mostEuropeanCountries
16,treatedWithIntraperitonealInjectionFor30Days
Other,commonMedications
Other,well-established
Mood,cancerControlPlanning
Testing,cytologicalExamination
Distinct,threeDifferentUsMachines
Testing,importanceOfNondestructiveTestingInDefectStudies
Other,infiltrativeLesion
Other,secondSurgery
Other,couldConsidered
TAMs,preclinicallyTams
Disease,cancer-relateddeaths
Neoadjuvant,administrationOfNeoadjuvant
Utilized,hasWidelyUsed
Alpha,sParticipants
Other,nano-biosensor
Other,connected
Provider,prognosticFactorIndependentOfOtherClinicalVariables
Other,tested
Other,treatmentTherapy
Young,femalePatient
Basis,whenGiven
Other,linked
Other,414Percecnt
Cell-killing,cell-killingEffect
Multiplex,multiplexAssay
Testing,fisherAnalysis
Other,imagingInvestigations
Other,illiterate
Cox,coxModel
Interference,disposition
Other,conventionalTreatmentProcesses
Water,excellentPerformanceInFieldOfMedicalImagesDiagnosis
Spread,breastCancerCellInvasion
Intensity,qualityEvidence
Other,termsOfKyotoEncyclopediaOfGenes
Other,vitalRoles
Intensity,qualityOfLifeOfPatients'Spouses
Infrared,infraredFluorescentImagingInTripleNegativeInVitro
Other,centralDenmarkRegion
16,about30Percecnt
Output,additionalIndicator
Other,cells
Other,shouldCo-managed
Other,earlyStageDiagnosisOfTumors
Other,volumes
Other,0.029
Other,moreLikely
Restoration,material
Other,protective
Other,tumorImaging
Caregiver,veryRareCaseOfTraumaticBreastNeuroma
Other,treatmentStrategies
16,22Patients
Other,diagnosisOfEstrogenReceptor
Signature,responseRate
Odds,average
Other,increases
Signature,lifestyleModification
Testing,microarrayAnalysis
Other,urgent
Other,futureInterventions
Conflict,activityOfCellProliferationInBreastCancerCells
Subtypes,biologicalSubtypes
Cohort,youngMen
Other,neglected
Other,analyzing
Other,metastaticDisease
Other,patients'Prognosis
Advantage,importantCopingResource
Prior,mayUsedForTumourShrinkagePriorToSurgery
Gene,PCDH10
Intensity,mass
Considerable,considerableNumber
Craniotomy,surgicalExcision
Other,characterized
Other,primaryTumours
Testing,clinicalBreastExamination
Testing,unbiasedRnaSequenceAnalysis
Other,lessVisits
Restoration,cancerCareSystems
Other,westernBlotAnalyses
Aberrances,multipleGeneticAberrances
Susceptibility,improvementInClassificationOfMalignantLesions
16,25CaseReports
MABA,conventionalBafifty-fivePatientsUndergoingViaMabaForPtmc
Accumulation,surveillancePopulation-basedData
Intensity,imageQuality
Other,described
Hazard,peakInRecurrenceRisk
Other,advances
Other,major
Other,australianSynchrotron
Output,capacity
Other,outcomes
Other,alexnetModels
Other,receptorActivator
Exposure,itsPerformance
Other,bt549Cells
Other,events
Traumatic,traumaticBreastNeuromas
Allele,tumorSuppressorGene
Radiotherapy,chemotherapy
Other,pathologists'Awareness
Other,samples
Users,non-nsaidUsers
Other,breastTumorMicroenvironment
Evolve,womenOfReproductiveAge
Susceptibility,changesToIntimateIssuesIncludingSexualHealth
Other,her2/hrTripleNegativeTnmStages
Other,diagnosis
Disease,invasiveDuctalCarcinoma
Other,treatmentMoreAccessibleToBreastCancerPatients
Scientific,criticalScientificBaseForPrecisionMedicineInBreastCancer
Exposure,limitedPerformanceForWomenWithDenseBreasts
Network,faSignalingNetwork
Conflict,anti-tumorActivity
Anastrozole,adjuvantAnastrozole
PCDH10,methylationStatusOfPcdh10InBreastCancerTissues
Subset,thatInMabaGroup
Other,rare
Factors,similarTendencyRelatedWithPrognosticFactors
Other,282Patients
Interference,haveStudiedInTermsOfCrosstalkBetweenEstrogenReceptorAlpha
Subset,baGroup
Other,associations
Actual,moreEffectiveTreatmentOfLungCancers
Other,causes
Ecchymosis,increasedRonExpression
Other,uptake
Other,Data
Atypia,nuclearAtypia
Components,specificCancerCell-relatedComponents
Other,knownHeterogeneousDisease
Other,heterogeneousPopulationsOfCellsWithHierarchicalOrganizationDrivenByCancerStemCells
Other,histopathologicallyProvedBreastTumors
Testing,testingDatasetsCollectedFrom48Patients
Other,westernizedCountries
16,patientsWithMAmongThem
Other,importantContributors
Other,dcisWithMicroinvasion
Accumulation,cnvData
Other,tissueMicroarray
Other,normalSamples
Other,84Patients
Other,betterPrognosis
Susceptibility,positiveChangesInTheirHealthBehaviours
Restoration,withDevelopmentOfHigh-throughputSequencingHaveDiscoveredInTumorousTissues
Other,guidedImagery
Forefront,forefront
Other,ourResults
Hazard,summaryHazardRatios
Other,differentialDiagnoses
93,93Percecnt
Symptom,effectOfBaicalinInBreastCancer
Cox,coxProportionalHazardRegressionModels
Subset,ligand-bindingDomainAllInBreastCancerSamplesFromPatientsPreviouslyTreatedWithEndocrineTherapy
Subset,thatInNon-pcrGroup
Strategy,mightPromisingTherapeuticStrategyForHormone-therapyRefractoryEr
Other,radiologicalSignsOfMalignancy
Cohort,bloodSamples
Alpha,30TBreastMagneticResonanceImagingExaminations
Levels,microrna-22ExpressionLevels
Other,classifiers
Cardiac,cardiacTroponins
Other,trastuzumab/pertuzumab/taxane
Discovery,detectionRateOfMutationsHigherThanThatDescribedInLiterature
Spouse,morcFamilyCw-typeZincFinger4Overexpression
Other,synthesized
Conflict,dual-phaseContrast
Other,mechanisms
Other,prognosis
Disease,cancer-relatedDeath
Clinical-pathological,empiricalTreatmentsBasedOnClinical-pathologicalCharacteristicsToUseOfTargetedApproaches
Other,hospitalFromJanuary2016ToFebruary2017
Testing,patients'MedicalRecords
ST-2,solubleSt-2Level
Amplification,inclusion
Replaced,isReplaced
Other,percecntRelapsedTissues
Other,documented
Elusive,howeverElusive
Conflict,strongContrastWithImagingModalities
Other,imagery
Considerable,reverseActiveLearningForClassificationOfHealthyBreastTissue
MiRNA-21,successfulFunctionalizationOfNanocompositeOfSpecificSequenceOfAminatedComplementaryOligonucleotideOfMirna-21
Cell,canOnlyDiagnosedOnPresentationOfSymptoms
FFDM,89FfdmCases
Quantification,successfulQuantification
Other,clarify
Other,fluorescenceImaging
Hazard,clinico-pathologicalRiskFactors
Other,severalPatients
Interference,backgroundParenchymalEnhancement
Strategy,potentialTreatmentStrategy
Subjective,personalGoal-setting
Focus,inPresentStudyConductedBetweenMcf-7Tamoxifen-resistantLcc2CellLines
Other,training
Values,seValues
Restoration,developmentOfLymphedema
Other,independent
Other,shapes
Caregiver,membraneTypeMr
Gene,STAT1
Mechanism,mechanism
Obesity,Obesity
Pleurodesis,pleurodesisForMalignantPleuralEffusion
Other,10.1
Mood,controlTrial
Symptom,oftenWellScrutinisedByPathologistsForEvidenceOfMetastaticCarcinomaAsImportantPrognosticParameterInStandardSetting
US,usExaminations
Other,visualizedTheranosticsOfTumors
Other,misdiagnosis
Other,henceMainlyBased
Danger,consensusOnAssociationBetweenExposureToDdt
Other,tumorigenesisOfBreastCancer
Other,3-timeAssessments
Other,noted
Other,bronchoalveolarCarcinomaUnrelatedToKnownMetastaticBreastCancer
Other,important
Other,five
Evolve,youngAge
Other,SVM
Other,percecntConfidenceIntervals
Other,consequencesForSurvival/relapse
Other,objectives
Interference,delivery
Other,positiveChanges
Other,iraqiWomenWhencomparedToWesternWorld
Subgroup,wordCloud
Other,moreRefinedStratificationThanAnatomicStageAlone
Contribution,lossOf020Quality-adjustedLifeYears
Contribution,highCoverage
16,M
Strategy,revisionsOfAjccBreastCancerStagingSystem
Other,DPV
Description,greatPromise
Considerable,significantAssociationBetweenRs5743810AllelicFrequency
Other,normalDucts
Resistance,thusWouldCrucialForApplicationOfPreventiveStrategies
Odds,averageOf425Â±496Ctcs/2Ml
Other,meanTime
Quantification,multidimensionalScaling
Analytics,dataAnalytics
BRCA1,soFarHasMainlyAssociatedWithMutationsInBrca1
Other,presented
Other,findings
Other,maintainedBreastCancerDatabase
Intensity,quality
Alpha,her2-positiveA
Other,secondLargestHmo
Testing,fisherDiscriminantAnalysis
Other,99Percecnt
Other,treat
Distinct,theirRelatedMarkersAtDifferentPointsOfChemotherapyRegimensInMetastaticBreastCancer
Other,logisticregressions
Actual,formulationOfEffectiveManagementPlanForAt-riskWomen
Other,consistent
Focus,firmlyPlaceWithRecentTrendsTowardDecreasedRatesOfRe-excision
Restoration,developmentOfSubsequentLung/bronchusCancer
Other,12-15Percecnt
Proliferation,osteopontin-750Accumulation
FOXC1,FOXC1
Transcripts,Transcripts
Other,bevacizumab-relatedCardiotoxicity
Proportion,prognosticSignificanceOfNeutrophil-to-lymphocyteRatioInPatientsWithBreastCancer
CTn,cTn
Species,Patients
Other,ductalCarcinoma
Other,smallerMyeloperoxidase
Caregiver,caseRecords
16,22Deaths
Other,Resurgery
Other,archivedFormalin-fixedParaffin-embeddedTissue
Other,1722Comments
Disease,breastCancerStaging
Other,managementOfTumour-relatedSymptoms
Other,changes
Sites,sixGlycosylationSites
Other,suggested
Other,most
Other,recommended
Other,canineTumours
Predominant,frequentCancer
Membrane,atrophiedVaginalMucosa
Other,Residents
Percent,rate
Hazard,theirRisk
Other,outliers
Gene,Protocadherin-10
Other,variousNon-pharmacologicalAdjuvantTherapies
Contribution,loss
Other,Wilm
Phenotype,roleOfImage-basedTextureFeaturesAsNoninvasivePrognosticBiomarkers
Bromide,patientSelectionForNon-pcosReferenceCohort
1-2,breastCancerPatientsWith1-2PositiveSlnspatientsWithBreastCancer
Other,insufficient
Other,mostCommonCancerInWomen
Other,kaplanMeierCurves
Other,49Patients
Other,51Days
Other,cases
Description,questionnaireBasedOnAnderson'SdelayModel
Hybrid,individualRiskOfRecurrence
Actual,20PercecntIncreasedRiskOfBreastCancerAmongCurrentHormonalContraceptionUsers
Detection,materialDetection
Gene,FXYD3
Pure,shouldProcessed
Evolve,inTotalDiagnosedUnderAgeOf50
Conflict,contrastAfterInjection
Other,closelyAssociated
Interference,postOperativeAssessment
Conflict,dynamicContrast
ER-positive/human,er-positive/humanEpidermalGrowthFactorReceptorType2-negativeBreastCancers
Biopsy,openBiopsyOfNodularityAttachedToPectoralMuscleFascia
Other,secondTumor
Other,molecularChanges
Other,ultrasound
Other,divided
Subtypes,accurateDiagnosisOfBreastCancerSubtypes
Purpose,crucialRole
Other,missed
Other,diagnosticEvaluation
Other,recentDevelopments
Binding,mir-193b-3pBindingTo3UntranslatedRegionOfMorc4
Other,seen
PCDH10,pcdh10GenePromoterMethylationIdentifiedInDuctalCarcinoma
Other,moreoverRemarkablyIncreased
Description,prediction
DDTs,expectedInverseCorrelationOfSerumDdtsWithBmi
Other,hasApplied
Disease,boneLoss
Discovery,researchLight
Other,delay
Reduced,diminishedOncospheroid-formingCapacityOfBreastCancerCells
Other,news
Contribution,coverageRates
Binding,site-specificBindingLeadingToImprovedCancerTreatmentWithMinimalRisksToNormalCells
Cell,canExtended
Testing,medicalStatus
Number,cssBenefit
Exposure,excellentPerformance
Purpose,aim
Cohort,prognosesOfYoungMenWithBreastCancer
Other,qualitativeApproach
Other,postponementVisiting
Other,histoneModifications
Chinese,chinesePublic
Disease,PCOS
Danger,documentedAsImportantTumor-promotingAgentForSeveralHumanCarcinomasIncludingBreastCancer
Parameters,morphologicParameters
Platinum,itsMinimalSilverIonReleaseProfiles
Other,similar
Other,DCR
Other,offered
Parietal,leftParietalRegion
Other,2=
Chemical,Estrogen
Propensity,propensityScoreMatchingAnalysis
Oligonucleotides,rnaOligonucleotides
Cohort,mostCommonCancerOfAdolescentsAgedAccountingFor56PercecntOfInvasiveBreastCancerInWomen
Survivors,535941Survivors
Caregiver,specialType
Exposure,nomogram
Other,splenicLymphocytes
Other,clinicalVisits
Situations,isReplacedWithRadiotherapyInSituations
Other,complaint
Entry,stableBodyWeight
Food,ourExperienceOfHigh-doseRadiotherapy
Other,0.001
Survival,survivalRates
Mood,greaterthanorequalto10PercecntDecline
Other,significance
Reduced,decreasedRisk
Exposure,performanceEvaluation
Other,mistakenDiagnosisOfMalignancy
Conflict,availableContrastAgents
Type,localizedDescriptionOfBreastCancer
Other,tumor-1
Testing,analysisInvestigate
Basis,given
Pathologically,firstPatientsWithPathologicallyTumor-freeNodes
Other,processing
Other,known
Restoration,cancerCareNetwork
Other,annualMammographyAssociatedWithEchography
MAb,mab1e3
Testing,nondestructiveTesting
Other,researchers
Intensity,haveValidatedByClinicalStudiesInCardiotoxicityDiagnosisInPatientsTreatedWithHighDosesOfAnthracyclinesAloneInCombinationMainlyWithTrastuzumab
Restoration,multidisciplinaryCare
Other,thenAdded
Actual,mostEffectiveTechniqueused
Other,importantComponent
Other,howeverMoreDrastic
Other,limitedLiterature
Other,histopathologicalreports
Ecchymosis,mir-511Expression
Other,It
Purpose,roleOfAutoantibodiesInEarlyCancerDiagnosis
Toxicity,minimumToxicityToNormalCells
Interval,axillaryClearance
Intensity,particularEmphasisQuantifying
16,20BreastCancerPatients
Other,program
Other,tissueDiagnosis
Targets,targets
Other,serious
Focus,sentinelLymphNodeBiopsy
Binding,mir-193b-3pBinding
Other,suutaneousBreastTumor
Species,participants
Pathologic,pathologicEvaluation
Systematic,age-matchedSystematicRandom-samplingMethod
Nonparticipation,resistanceToMultipleTypesOfTreatmentInBreastCancerModels
VAP-1,vap-1NegativeStaining
Conjugates,antibodyDrugConjugates
Ovarian,ovarianCancer
Heterogeneity,heterogeneity
Chosen,fewPercentOfWomen
Factor,factorAnalysis
Conjugate,anti-ronMonoclonalAntibodyZt/g4-drugMonomethylAuristatinEConjugate
Purpose,roleOfSupportOfferedByVirtualCommunitiesToBreastCancerPatients
Other,cpgIslands
Focus,highDetectionRateOfSentinelLymphNodeComparableWithRiMethod
Testing,comprehensiveSearch
Other,Depletion
Spouses,spouses
Mutations,mutations
Disease,tumour
Signature,haveDescribedInResponseToNeoadjuvantChemotherapyParticularlyInAssociationWithHerceptinTreatment
SLN,slnMetastasis
Platinum,haveBackboneOfSuchEnormousStridesOfAu
Adulthood,prospectivelyFollowedFor3YearsSinceDiagnosis
Signatures,efficientSignaturesForClinicalDiagnosis
Other,contexts
Care,concernForExistenceOfCancerCellsInGrafts
Other,overnight
Other,pcrThanWomenWithHr-positiveTumors
Individuals,Individuals
Other,NLR
Other,kind
Other,theResulting
Collision,theirQuestionableImpactOnMortalityOnIncidenceOfAdvancedTumors
Other,Ontario
Signature,diagnosisOfResponseToTreatment
Other,twoImagingIndexes
Seven,sevenWomen
Other,patientsWithMetastaticBreastCancer
Syndromes,syndromes
Other,life
Global,globalHealth
Hybrid,carrier
Cohort,youngMexicanWomen
Nonparticipation,tamoxifenResistance
Testing,henceMajorResearchGoal
Adult,activeNon-participants
Danger,exposure
Various,variousMethods
Intensity,overallLowOfSixCirculatingMirnas
Testing,previousCervicalCancerScreening
Discovery,detectionOfCancer
Other,secondary
Other,importantPotential
Danger,cause
Other,pairedUntreatedPrimaryTumor
Other,medications
Apoptosis,apoptosis
Conflict,physicalActivity
Hazard,riskForRecurrence
Ecchymosis,inhibition
Disease,brainMetastasis
Other,markedlyUp-regulated
Purpose,purpose
Other,iU22
Other,mriImaging
Adult,active
Benchmark,target
Intensity,value
Distinct,successOfSymmetricPositiveDefiniteMatrices
Other,mortalityRates
Technique,novelPowerfulTechnique
Other,breastImagingModality
Testing,medicalDiagnosisOfBreastCancer
Other,filipinoWomen
Caregiver,membraneTypeMannoseReceptor
Other,factor-1Scores
MiR-511,miR-511
Intensity,suchLowIncidence
Distinct,willDifferentRegardingSubtypeAtDiagnosis
Sensitive,sensitive
Focus,axillaryLymphNode
Other,kaplan-meierCurves
Food,ourExperience
Radiotherapy,neoadjuvantChemotherapy
Other,her2-positiveInvasiveDuctalCarcinoma
Hypomethylated,moreEasilyHypomethylated
Other,demonstrate
16,shorterIntervalsBetweenD
10-year,breastCancer-specific10-yearSurvival
Biopsy,stereotacticWire-guidedBiopsy
Other,mostInvasiveDisease
Other,included.When
Benchmark,potentialTherapeuticTarget
Disease,cytotoxicity
Nonparticipation,chemotherapyResistance
Adulthood,riskOfBreastCancerInAdulthood
CTC,CTC
Interference,theirBeliefsRegardingCancerCausation
Other,matched
Utilized,nowAlsoWidelyUsed
Subgroup,17MillionPeople
Other,incidence
MiRNA,mirnaExpressionProfiles
Mood,control
Other,MortalityRates
Other,utility
Considerable,significantHigherRisk
Other,relation
Other,switch
Mood,acuteDangerToMother
Other,unclear
Other,diet
Other,diagnosisOfGallbladderMetastasis
Danger,secondLeadingCause
16,100Patients
Coefficient,correlationCoefficientOnMetabricTrainingSet
Estrogen-alone,preventionOfDiagnosedBreastCancerInEstrogen-aloneArmOfWhi
Revealed,additionallyRevealed
Adulthood,adulthood
Other,estimated
Adulthood,twoYears
Other,Immunohistochemistry
Fertility,flowRate
Obstetrician,pathologistAnnotation
Targeted,elusiveToTargetedTherapies-theTriple-negativeBreastCancer
Other,electiveCholecystectomyForSymptomaticCholelithiasis
Description,zebrafishTumorModel
Description,resultOfPreviousOrbitalBiopsy
Postmenopausal,952PercecntOfthePostmenopausalWomen
Testing,comparisonToCa15-3
Other,independentPrognosticPredictor
Other,detailedRoles
Conflict,physicalActivityInPatientsWithMetastaticBreastCancer
Cohort,poorPrognosis
Neuromas,breastNeuromas
Other,significantlyYounger
Cohort,young
Ecchymosis,enforcedExpression
Cohort,poor
Hazard,poorerOutcome
Postmenopausal,postmenopausalPatient
Other,patientsOnAromataseInhibitors
Other,usuallyAssociated
Cox,multivariateCoxProportionalHazardRegressionAnalysis
Restoration,goodCorrelationBetweenErAnalysedWithCytAtDiagnosisAnalysedWithIhcInArchivedFfpeTissueFromSameTumour
Other,undiagnosed
Reduced,small
Considerable,partialPathologicalResponseWithLargeAreasOfTumourRegression
Discovery,likelihoodOfDetectionOfMicrometastases
Provider,patientsWithHumanEpidermalGrowthFactorReceptor2
Cohort,breastCancerAged
Entry,assessedinclusionCriteriaForEnrolment
Distance,tumorNippleDistance
Evolve,stratifyingForAge
Alpha,initialPresentationOfInvasiveBreastCancer
Other,whereDeveloped
Focus,haveReportedForFirstTimeInCaninesInStudy
Other,significantlyCorrelated
Isolation,univariableLogisticRegressionModels
Simulated,simulatedBreastCancer
Other,chapter
Factors,factorsRelatedToPresenceOfMetastaticDiseaseAtDiagnosis
Pathologic,dependentOnRigorousPathologicEvaluationOnAdministrationOfTreatmentDictatedByTumorBiology
Benchmark,significantlyHigherBaselineBpeLevelsThanPostmenopausalWomen
Other,mean
Radiotherapy,chemotherapyGroups
Chemical,melatonin
Will,understandingOfEmergingConceptsOfTumorBiology
Spouse,caseOf68-year-oldCaucasianFemaleWithFamilyHistoryOfCancer
Other,identifiablePcrResults
Platform,clearcellPlatform
Water,essential
Testing,PM
186,186S
Number,increaseWithNumberOfSprays
Other,surgery
Other,workflowConsistingOfImmunoaffinityPurification
Food,goal
Other,breastCancerPatientsSerum
Issues,issuesRelatedToTherapeuticSequencingInLocalTherapyOfBreastCancer
Other,independentlyAssociated
Other,single-cellWhole-exomeSequencing
Testing,westernBlotAnalysis
Other,importantProblem
Other,thereforeApplied
Other,breast
Other,0.32
Gene,HR
Other,133BreastCancerCases
Discovery,ca15-3Detection
Collision,injury
186,186Pathology-provenS
Signature,interval
Restoration,clinicalCharacteristicsOfCareOfBreastCancerPatients
Other,team
Other,12404Patients
Other,twoScales
Immunohistochemistry,erImmunohistochemistry
Other,rareTumor
Other,awareness
Other,976PercecntSensitivity
Other,quantitativeRealTimeFluorescencePolymeraseChainReaction
Craniotomy,excision
Other,hasPut
Restoration,healthCareSector
Purpose,willTested
Purpose,aspirinUse
Other,enhancedPossibility
Other,controversial
Other,erCscs
Other,.014
Apatinib,tolerabilitytheApatinib
Other,oftenRelated
Cell,cancer-relatedEventsIncludingTumorCellMigration
Sensitive,classified
KDM4B,scffbxo22-mediatedKdm4bDegradation
Other,428BreastCancerPatients
Other,improvedDiagnosis
Presentations,rareClinicalPresentations
Other,those
Other,only35Cases
Other,enrolled
Other,investigated
Other,amplifications
Other,clinicalCharacteristics
Other,conventionalX-rayMammography
Other,pregnancy
Sensitive,thenClassifiedBySupportVectorMachines
Other,lymphocytes
Accumulation,data
Other,harmfulorHarmlessTissues
Restoration,ourFacility
Other,oestrogenReceptorPositiveIn58PercecntOfCasesPositiveIn62Percecnt
Other,thoseWithHr-positiveTumors
Other,referral
Restoration,developmentOfBrainCancers
Cytology,intraoperativeScrapeCytology
Hereditary,hereditaryCausesOfChorea
Platinum,chlorambucilPlatinum
Other,statisticallyCorrelated
Other,real-worldSetting
Other,resources
Learning,separateClassificationModels
Discovery,detectionRate
Other,thenPresented
Other,0.003
Restoration,moreoverPerformedOnMcf-7CellLineInPresenceOfCs/bio-mofCarrier
Evolve,evolveTowardLessSurgery
Intensity,qualityOfLife
Ecchymosis,itsExpression
Description,model
Complex,acid
Other,novelNavigationSurgery
Other,omission
Other,902Percecnt
Considerable,significantAssociationBetweenLevelsOfNek6
Distinct,different
Predictors,traditionalPredictors
Distinct,differentPrognosis
Other,PI3K/AKT/mTOR
Global,17MillionPeopleWorldwide
16,17Years
Other,773Percecnt
Other,regulated
Other,4248BreastCancerPatients
Focus,descriptiveStudy
Other,trend
Actual,effective
Output,paper
Testing,histologicalExamination
Restoration,perceptionOfQualityOfCareProvidedByCancerCareNetworkForEarlyDetectionOfBreastCancer
Other,promoterMethylationStatus
Glycosylation,glycosylation
Other,mostFrequentlyOccurringCancer
Estimates,estimates
Spread,fewerInstancesOfSpreadToLungs
Other,betterResults
Other,moreoverStronglyRecommended
Restoration,inStudyFusedWithMouseMyelomaCellLineSp2/0InPresence
Other,moreRecommended
Advantage,advantage
Urgent,urgentCytology
Intensity,signalIntensity
Conflict,dealingWithEndocrineResistanceInPatientsWithBreastCancer
Sensitive,sensitiveNano-genosensor
Distinct,differentProtocols
Sensitive,highlySensitiveNano-biosensor
Numerous,manyResearchers
Monte,monteCarloFeatureFeatureMethod
Hybrid,geneticMutation
Other,stageI/iiaCases
Other,Referrals
Intensity,prognosticValue
Cohort,peripheralBloodSamples
Other,42
Other,diagnosed
Other,areas
Other,earlyCancerDiagnosis
Finding,locoregionalDiseaseOfUnspecifiedLocation
Asymptomatic,asymptomaticWomen
Other,useful
Disease,invasiveBreastCancer
Other,controls
Other,adjacentNon-tumorousTissues
Other,painlessLumpInBreastAccountingFor688PercecntOfPatients
Other,protected
Other,pairedTumor
Elusive,elusive
Subgroup,associationOfToll-likeReceptor6WithBreastCancerInSaudiArabianWomen
Description,randomEffectsModel
Other,cylindricalGeometries
Intensity,highMortalityRateForFemales
Testing,effectivenessOfNationalScreeningProgrammes
Resistance,greatPotentialOfClinicalApplication
Other,cscMarkers
Canines,canines
Other,methylation
Survival,theirSurvival
Intensity,highVolumeAcademicCenters
Contribution,urgentlyAdvanceImplementation
Other,Patients
Other,recognized
Other,notablyDesigned
Necessity,immediateUnmetNeedInClinicalPractice
Other,results
Sleep,fastDayBefore
Other,potential
Other,psychologicalAspects
Other,options
Locoregional,locoregionalRadiotherapy
Researchers,Researchers
Focus,third-lineTreatmentForAdvancedTriple-negativeBreastCancerthisRetrospectiveStudy
Lymphedema,lymphedemaPatients
77,77Patients
Other,differentialDiagnosis
Purpose,importantRole
Therapy-related,therapy-relatedConditionsDuringBreastCancerSurvivorship
Benchmark,baselineBpeLevels
Hazard,associatedWithBreastCancerRisk
Other,fiveGroups
Survival,progression-freeSurvival
Hazard,RiskProtection
Caregiver,typicalWoman'sDisease
Distinct,differentContrastAgent
Other,95PercecntConfidenceIntervals
Other,doses
Finding,growth
Conflict,adverseEventsExceptDegreeI-iiBleeding
Type,description
Other,agents
Other,multigenePanels-with
Focus,retrospectiveStudyOfWomenTreatedWithTrastuzumabForHumanEpidermalGrowthFactorReceptor2BreastCancerAtMayoClinicBetweenJanuary12000
Mood,variablesPredictiveOfNippleAreolaComplexInvolvementInPatients
Other,little
Nonparticipation,feasibleCtcIsolationTechniques
Neuroma,neuroma
Proliferation,proliferationOfMcf-7Cells
Cell,canIncluded
Description,multiresolutionResult
Care,extensiveAttentionOfResearchers
Testing,screening
Other,therapeuticEffectsInBreastCancer
16,greaterthanorequalto10PercecntReductionInLvef
Hybrid,mutationRatio
Isolation,binaryLogisticRegressionModels
Other,myeloperoxidase
Hybrid,mutationEvents
Other,synthesisMethods
Other,functionalAssessments
Testing,bioimpedanceAnalysis
Other,knowledge
Capillaries,capillaries
Gene,MORC4
Purpose,associationBetweenPost-diagnosisLow-doseAspirinUse
Disease,breastTumor
16,5Of10Patients
Intensity,dramaticallyIncreasedAmount
Other,earlyDiagnosis
Other,tumorEasily
Survival,survivalDifferences
Survivors,quality-of-lifeFactorsForSurvivorsIncludingSexualDysfunction
Circulating,expressionOf6CirculatingMirnasInOperablePatients
Other,pregnancyFrom1959To1966
Disease,lungCancer
Disease,breastCarcinoma
Phenotype,alongsideRoutineMethodEmployedOnTexture
Other,2IndependentCohorts
Other,calculated
Accumulation,surveillanceData
Proliferation,molecularPathwaysInvolvedInPathogenesisOfProliferation
Other,bilateralSalpingo-oophorectomy
Phosphorylation,phosphorylation
Other,tissues
Disease,cardiacInjury
Other,proteinKinase
Discovery,earlyBreastCancerDetectionSystems
Benchmark,rationaleForTamsAsTherapeuticTargetInBreastCancer
Survival,radiation
Distinct,effectivenessOfDifferentNpatsOnQolInPatientsWithBreastCancer
Other,potentialImportanceAsModelsForHumanBreastCancer
Other,kinds
Other,undergone
Mood,complex
Survival,three-yearSurvivalRates
Contribution,aromataseInhibitor-inducedBoneLoss
Other,incidenceRates
Other,organotropic
Other,prognosticStagingSystems
Other,locallyAdvancedBreastCancer
Other,clinico-pathologicalFeaturesOfMetastases
Subjective,subjectiveRisk
Proportion,tumor-to-backgroundRatio
Disease,hereditaryDisease
Other,administered
CEDM,49CedmCasesCollectedFromMayoClinic
Other,higher
Conflict,strongContrast
Enhancer,enhancerRegions
Other,sensitivity
Other,sustainedStableDisease
Caregiver,70-year-oldWoman
Other,queried
Restoration,goodQualityEvidence
Restoration,good
Danger,associationBetweenNsaidsExposureInFemalePatientsWithAd
Testing,moreIntensiveFollow-up
Focus,place
Mood,breastCancerControlEffortsForIdentification
Intensity,proportion
Other,dissectionOfLymphNodes
Cohort,blood
Chemical,Baicalin
Relapse,relapseRates
Other,howeverNon-ideal
Signatures,collectedSignatures
Traumatic,traumaticNeuroma
Numerous,numerousGene-expression-basedPrognosticSignatures
Base,basis
Cox,coxHazardRegressionAnalysis
Nonparticipation,involvement
Other,adherenceToRecommendationWith95PercecntConfidenceIntervals
Description,challenge
Other,768PercecntSamplesWithOverexpressionIn76Cases
Other,fourTypesOfBreastCancer
Survival,littleSurvivalVariance
Disease,fibroadenoma
Ecchymosis,geneExpressionUpregulationInBreastCancer
Young,193FemaleParticipants
Other,appropriateSequencing
Mood,2-groupRandomizedControlTrial
Other,sulass
Other,moreInclined
Other,compared
16,13Percecnt
Other,breastCancerMetastasis
Targeted,targetedTherapies
Exposure,performance
16,30DoublingTimesNecessary
Other,metastasisFromLobularBreastCarcinoma
Other,regulationOfNras
Strategy,nirFluorescenceImagingSystem
Other,critical
Other,expressed
Discovery,detectionOfMicrocalcificationInMammograms
Other,China
Intensity,associatedWithPfsAlthoughAtExtent
Considerable,significantAdvances
Purpose,time-varyingPost-diagnosisLow-doseAspirinUse
Other,algorithm
Other,denseBreasts
Other,distributions
Other,ribonucleotideReductaseM2
Other,studies
Disease,LVEF
Other,nature
Other,crucial
Susceptibility,healthBehaviours
CMIA,ca15-3ByCmia
Testing,furtherResearch
Targeted,moreTargetedAdjuvantTreatments
Other,clinicalRecords
Alpha,initialTreatmentAfterWhich
Other,diagnosticUncertainty
Other,variables
Pathologically,pathologicallyTumor-freeNodes
Other,product
Other,widelyExpressed
Percent,fastRate
Other,moreRecentlyHaveDeveloped
Other,discussed
Isolation,kaplan-meierRegressionMethods
Restoration,megakaryocyteMarker
Other,suutaneousLymphaticChannels
Purpose,diagnosticRole
Adult,netherlandsCancerRegistryOf37230PatientsWithEarlyBreastCancer
Microfluidic,microfluidicChips
Basis,particular
Reverse,reverseTranscription-quantitativePolymeraseChainReaction
Description,clinicalPicture
Axillary,axillaryDissection
16,40
Other,painless
Other,scrutinised
Hazard,riskFactors
Restoration,oneExtraVisit
Mechanism,potentialMechanismForFoxc1-inducedMetastasis
Hazard,riskStratification
Alpha,fluorescenceImagingExVivo
GTPase,gtpaseInBreastCancerCells
Bromide,referenceForClinicians
US,usStandardization
Alpha,a
Intensity,volume
Other,Diseases
Interference,assessmentOfImpactOfAdvancesInDiagnosisOfPatientsWithBreastCancer
Benchmark,exon32OfMammalianTargetOfRapamycin
Disease,choreiformMovements
Supplements,promisingSupplements
Other,secretion
Survival,medianProgression-freeSurvival
Stigmatization,stigmatization
Discovery,detectionOfBreastCancerInWomen
Other,modeled
Other,nextMade
Hazard,highlyDiverseGroupOfMalignantNeoplasiaWithPoorOutcome
Black,blackWomen
Subset,highestSeInTotalGroup
SNPs,SNPs
Replaced,replaced
Spouse,spouse
Chemical,diindolylmethane
Other,malign
Other,imaging
Other,geometries
Restoration,at25HPost-injectionGreaterInTumorBedThanInKidneyRespectively
Disease,sexualDysfunction
Other,observed
Users,12331Users
Disease,OS
Subsequent,subsequentPrimaries
Revealed,revealed
Radiotherapy,radiotherapy
Other,characteristics
Other,2012AtBreastClinicOfPortugueseInstituteOfOncologyInPorto
Purpose,objectiveResponseRate
Other,Delays
Variants,variants
Goal-setting,goal-setting
Other,mostFrequentlyDiagnosedCancer
Baseline,baselineSolubleSt-2Level
Other,considered
Computer,Computer
Mood,mood
Other,properImaging
Mood,60ControlPatients
Hazard,hazardRatiosWith95PercecntConfidenceIntervals
Overexpression,Overexpression
CNVs,CNVs
Other,2009-13
Pearson,Pearson
Regimens,newTreatmentRegimens
Robust,richSpectralFeaturesOfPhenyboronicAcid-basedNanoprobe
Other,manifold
Township,prognosisOfPatientsWithMaleBreastCancerInShanxiProvinceOfChinaFrom2007To2016
Distinct,mayDistinctEntity
Other,hasProposed
Township,township
Adulthood,medianFollow-upOf48Years
Alpha,oestrogenReceptorAlpha
Testing,age-basedScreeningPrograms
Other,tanUsage
Subset,group1
FFDM,FFDM
Other,analyses
Nanocarrier,nanocarrier
Distance,totalHemoglobinConcentration
Syndrome,syndrome
Other,created
Provider,independentPrognosticFactor
Other,NAC
Other,SVM-BRC
Fertility,cellCycleRegulators
Protocols,treatmentProtocols
Type,edition
Other,visits
Other,followed
Caregiver,case
Users,users
Other,fiveYearRfsrate
Cutoff,cutoff
Other,992PercecntOfCases
Manufactured,manufactured
Distinct,differentPhotosensitizerForPhotodynamicTherapy
DDTs,DDTs
Other,0.02
Filter,intravenousAdministrationOfOsteopontin-750Probe
Purpose,contraceptiveUse
Other,andfemales
Treatments,selectedStandardTreatments
Other,doublingTimeOfOccult
Conjugate,conjugatedEquineEstrogen
Formed,formed
Learning,learning
Entry,body
Other,its
Other,diagnosisOfCancer
Disease,HT
Symptom,effect
Yoga,intralaboratoryValidationSet
Disease,anxiety
Mood,breastCancerControlEfforts
Spouse,familySupport
Actual,currentFollow-up
Reduced,significantlyDecreased
Infrared,infraredFluorescentDye
Other,
Specimen,specimen
Treatments,treatments
Sites,sites
Other,promising
Sites,otherSites
Other,ongoingTrials
Hazard,surgicalOutcome
Other,historyOfBreastCancer
Obstetrician,obstetrician
Disease,cancerGenomeAtlas
Techniques,techniques
Required,required
Other,cutaneousManifestationsOfBreastCancer
Axis,combination
Binding,supportVectorMachine
She,She
Nanoplatform,nanoplatform
Ecchymosis,highGlut1Expression
Phenotype,phenotypeExpression
Gene,BRCA1
Allele,rs5743810ProAllele
DNA,dnaMethylation
Distinct,preciseToolForTargetedTreatmentOfCancerIncluding
Considerable,frequentLargeSingleGiantCellsWithNucleiLocatedPredominantlyWithinSupsularSinuses
Switched,switched
Other,performed
Bromide,periodOfObservation
Mood,rangingFromDiagnosisPhaseToControlOfDisease
Gene,VEGF-D
Issues,issues
GTPase,GTPase
Other,determining
CTC,ctcCounts
Disease,tumors
Post-NAC,post-NAC
Purpose,vitalRole
Entry,trastuzumabInitiation
Atypia,atypia
Other,recurrence
Disease,breastCancerDiagnosis
Food,embeddingIntoReproducingKernelHilbertSpace
Propagation-based,propagation-basedPhase-contrast
Other,broadcasted
Hypomethylated,hypomethylated
Other,commonMalignantDisease
Other,tamoxifen-resistanceInErCancerCells
Other,likelihood
Hazard,increasedRiskOfEndometrialCancer
Cytology,cytology
Hazard,increasedRiskOfMortality/relapse
Food,symptomaticHeartFailure
Simulated,simulatedInnerBreastTissue
Other,HADS
Global,worldwideHighestAge-standardizedBreastCancerIncidence
Reduced,significantlyReduced
Restoration,surgicalImplantationReconstruction
Signatures,signatures
Care,healthcareCost
Other,englishLiterature
Other,tests
Other,appropriateInterpretation
Subgroup,generalBreastCancerPopulation
Annexin,annexinVStaining
Hazard,earlyBiomarkersOfBreastCancerRisk
Other,.021
Other,mostPatients
Number,correspondingCohort
Other,minimal
Testing,alternativeContrast-enhancedScreeningTools
Other,-916
Susceptibility,healthExpectancyOfItspopulation
Other,mostCountries
Susceptibility,tertiarySexualHealthCenters
Yoga,metabricTrainingSet
Nonparticipation,endocrineTherapyResistance
MiR-34s,anti-oncogenicRegulationOfMir-34s
Osteopontin,osteopontinPeptide
Other,southernPortuguese
Danger,commonCause
Other,novelty
Mood,excellentRegionalControl
Delays,withandControllingForTreatmentDelays
SLN,positiveSln
Restoration,usualCare
Other,main
Other,Targeting
Other,D538G
Other,typicalHormone-dependentTumor
V-G,n-typeVoltage-gatedV-gCalciumChannelBindingAntibodies
Other,extensiveMolecular
Focus,inStudyDevelopedByCell-selex
Biopsy,slnBiopsy
Other,selectedPatients
Other,estrogenReceptor
Susceptibility,proactiveManagementOfPsychologicalHealth
Benchmark,thereforeCentralTarget
Other,quadrantectomy
Entry,initiationOfBreastMalignancy
Other,increasedMalignantPotential
Nucleus,sox9NucleusEntry
Other,determined
Strategy,risk-stratifiedScreeningStrategy
Danger,commonCauseOfMorbidity
Other,assessments
Parameters,ivimParameters
Cytology,breastCancerGenetics
Other,navigationSurgery
Nondestructive,nondestructiveTests
Other,additionallyCorrelated
Other,tumorUptake
Other,literature
Other,131Percecnt
Testing,breastScreening
Subset,group2
Other,popular
Description,survivalPrediction
Other,biomarkers
10-year,10-yearBreastCancerSurvival
Other,Biomarkers
Necessity,need
Other,immune-mediatedCancer-associatedDisorders
16,40Percecnt
Considerable,statisticallySignificantValuesAt4Cells/7MlBlood
Disease,primaryTumor
Disease,invasiveBreastCarcinoma
Other,Non-linearity
Other,wavelengthConsistencyIndex
Cell,canCategorized
Mood,commonEndocrineDisorder
Other,survivalDistributions
Cohort,youngWomen
Young,65-year-oldFemale
Other,proposedAlgorithm
Hazard,outcomeInLymphedemaPatients
Other,womenWithBreastCancer
Late-stage,late-stageCancerDiagnosis
Other,treated
Other,hasInconsistent
Chemical,tamoxifen
Other,MethyLight
Adulthood,recentYears
BRCA1/2,pathogenicVariantsInBrca1/2
Other,autonomyOfPatients
Distance,boneDensity
Trastuzumab,trastuzumabTherapyForBreastCancer
Species,patient
Other,nslnMetastasis
Other,incidenceAmongMalignancies
Caregiver,practitionerDecisionmaking
Interference,pre-operativeAssessment
Other,state-of-the-artAlgorithms
Other,interview
Other,breastCancerTissues
Radiotherapy,chemotherapyRecommendations
Other,portugueseWomen
Other,6Months
Gene,microRNA-22
Robust,strongIndependentPrognosticFactor
Other,hasSuggested
Survival,survivalVariance
Other,positive
Other,humanLife
Other,profile
Entry,colonyFormation
Subsequent,subsequentMalignancies
Treatments,non-standardPromptTreatments
Adult,whenActiveUse
Other,collected
Fertility,potentialImpactOnFertilityAfterTreatment
Testing,combinedAnalysis
Other,serumSamplesFromCancerPatients
Purpose,facilitatingRole
Other,overview
Benchmark,optimalTherapeuticTargetForPatientWithAdvancedBreastCancer
Other,all
Other,betterOutcomes
Other,0.007
Conflict,643PercecntWithSignificantDifferenceBetweenWhites
Chosen,throughOptimizationTestsChosenAsOptimalConditions
Hereditary,geneticChanges
Other,rnaKnockdown
Craniotomy,keysToSuccessfulChestWallResectionForLocallyRecurrentBreastCancerAfterMastectomy
Other,unusual
Actual,comparisonOfPredictedIncidenceOfBreastCancerWithActualIncidenceInPopulation-basedStudies
Variants,single-nucleotideVariants
Other,following
Contribution,mainContribution
Restoration,mayGoodChoiceForUnilateralPtmc
Other,poorerPrognosisInWomenWithBreastCancer
Other,Cryopreservation
Other,significanceLevel
Restoration,theirCare
Purpose,willUsed
Sites,keyHypomethylationSites
Other,cancerMolecularDiagnosis
Testing,analysisOfLncrnaExpressionProfiles
Other,cancerCells
Other,shouldKept
Ecchymosis,expressionLevel
Collision,recurrentWords
Other,OP
Water,field
Caregiver,type
Other,importantForDiagnosis
Other,breastCancerConfinedWithinMammaryDuctsSurrounded
Other,found
Antibody,murineMonoclonalAntibodies
Chosen,veryRareClinicalEntityWithOnlyFewCasesHavingReportedToDate
Other,Mechanisms
Reporter,luciferaseReporterAssay
Other,antibodies
Finding,thereforeHasAppliedToEarlyIdentification
Other,nodalMegakaryocytes
Distinct,differentStages
Lymphedema,unilateralBreastCancer-relatedLymphedema
Genes,highlyPenetrantGenes
Other,recurrence-free-survival
Description,fbxo22-dependentManner
Other,YS
Cell,canEasilyExtended
T2,irregularHyperintenseLesionInT2InLeftParietalRegion
Other,MicroRNAs
Caregiver,typicalWoman
Resistance,importantApplicationProspects
Other,alsoAssessed
Predominant,mostPrevalentMalignancyDiagnosedInPregnancy
Entry,appearance
Food,inAssay
Other,Utilization
Caregiver,unusualCaseOfPtosis
Focus,inStudyDevelopedForHighlyEfficientIsolationOfCtcsFromBreastCancerPatients
Limitations,limitations
NSAID,nsaidUsers
Distance,firstTime
Will,preoperativeUnderstanding
Cell,breastTumorProgressionIncludingTumorCellGrowth
Other,receivedWithoutSurfaceModification
Global,commonMalignancyWorldwide
Alpha,eConcentration
Other,retrospectiveStudies
Restoration,relativelyGoodPrognosisWith5YearOverallSurvivalOf88Percecnt
Hazard,breastCancerRisk
Other,percecnt
Alpha,dataOfN=
Other,anticipated
Other,effects
Other,radioisotope
Cohort,elderlyPatients
Other,diagnosisOfSulinicalPrimaryCarcinomas
Mechanism,theirContraceptivePreferences
Other,relapse
Endocrine-resistant,potentialTreatmentStrategyForEndocrine-resistantBreastCancers
Restoration,rolePlayedByPdgfFamilyMembersInNormalDevelopmentOfBreastTissueDespiteItsPotentPro-lymphangiogenicEffects
Mood,haveAssociatedWithNippleAreolaComplexInvolvementInPatientsWithBreastCancer
Other,olderWomen
Strategy,antibody-basedStrategy
RON,RON
Other,tumorCells
16,panelOf25GenesInvolvedInMechanismsOfTargetedTreatmentResistanceIn16PrimaryBreastCancersDevelopedDuringTreatment
Other,two-thirdsOfBreastCancerCases
Other,able
Other,their
Other,inMultivariateModelsRelatedToPerformanceStatus
Hazard,cardiotoxicRisk
Species,nudeMice
Focus,lymphNodeMetastasisInPatientsWithBreastCancer
HER2,her2Status
Other,specificCircumstances
Intensity,emergingPublicHealthProblemInLowCountries
Consensus-based,consensus-based
Hazard,cancerRiskPerception
Acupuncture,Acupuncture
Other,onEsophagogastroduodenoscopyIdentifiedInAntrum
Other,onlyWomen
Kazakhstan,sixteenRegionsOfKazakhstan
Base,advancedBreastCancerBearingMutations
Susceptibility,pb-ctMode
Other,Findings
Other,CTIBL
Areola,sideEffectsOfBreastCancerTherapiesIncludingHotFlushes
Desirable,desirable
Spread,invasion
Binding,bindingToBreastCancerCellsInVitro
Other,breastCancerStudies
Other,consultations
Subtype,specificSubtype
Other,score
Other,thusMeaningful
Distance,firstSteps
Other,pathway
Restoration,riskOfDevelopmentOfGliomas
Actual,currentCancerResearch
Other,status
Other,synonymous
Other,coding
BPE,decreasedBpe
Entry,probablyTranscriptionalActivation
Other,biomarker
Distinct,differentPatientRaces
Restoration,goodDiagnosticPerformance
Amplification,fxyd3Amplification
Other,increased
Testing,rnaSequenceAnalysis
PFS,PFS
Other,collapsing
Distinct,differentStudies
16,11Days
Restoration,betterOutcomeWithGoodNegativePredictiveValue
Other,51Patients
Subjective,women'sPersonalGoals
Other,stratification
Other,hormoneReceptor-positiveTumors
Disease,micrometastasis
Description,resultCompatibleWithMetastasisToOrbit
Other,safety
Global,mostPrevalentMalignancyAmongWomenAroundWorldAreDiagnosedYear
Intensity,asInCaseShouldAlwaysKeptInMindSpeciallyInHighVolumeCenters
Other,double-maintenanceTherapy
Platform,copyright
Cell-killing,cell-killingEffectInTriple-negativeSubtypeMda-mb-231Cells
Allele,dominantArms
Other,oneRegion
Conflict,significantDifference
Discovery,areaOfResidence
Other,fitted
Platform,area
Neoadjuvant,neoadjuvantTreatment
Sites,hypomethylationSites
Other,deep-CNN
Intensity,massProduction
Other,125DogSeraSamplesIncluding75MammaryTumourSera
Other,symptoms
Other,shouldProceede
Other,undergoing
Ecchymosis,glut1Expression
Testing,concentrationsOfVegf-aInComparisonToCa15-3InBreastCancer
Other,individuals
Personalized,mustIndividualized
Germline,244GermlineVariants
Cox,coxProportionalHazardModel
Other,thusAimed
Other,methods
Technique,inexpensiveTechnique
Prevention,needsInPrevention
Disease,metastases
Other,mastectomy
Necessity,necessity
Neoadjuvant,neoadjuvantSetting
Disease,breastCancers
Will,improvedUnderstanding
Species,Women
Binding,drugBinding
Other,utilization
Other,ranging
Distinct,differentFunctionRegions
HER2,achievedForHer2Status
Provider,relatedTranscriptionFactorSox9
Conflict,deathInWomenWorldwide
Membrane,combinedPanel
Other,variousArtifactsIntroducedDuringSlidePreparation
Filter,specificEralpha-targetedProbe
Intensity,significantlyCorrelatedWithTumorSize
Collision,greatClinicalImpactForTumorDiagnosis
Estimates,long-termEstimates
Areola,sideEffects
Third-line,capecitabineRegimenAsThird-lineTreatmentForAdvancedTriple-negativeBreastCancer
DNA,aberrantDnaMethylation
Other,pre
Restoration,developmentOfNewDrugs
Other,based
Other,tissueStorageTime
Entry,heterogeneousDiseaseInItsHistologicAppearance
Other,achieved
Other,OR
Other,concerns
Participants,participantsWithBreastCancer
Other,postmenopausalwomen
Race/color,forRace/colorVariableEstimatedWithAdjustmentForStatus
Evolve,threeYearsBeforeAge64Years
Purpose,willUsedAsReferences
Correlation,uncouplingOfInverseCorrelationBetweenBmi
Mood,moodOfLife
Other,assessed
Other,poorerPrognosis
Other,conservativeTreatment
Values,theory
Purpose,ourAim
Alterations,esr1Alterations
Periods,longerPeriods
Young,38-year-oldFemale
Almaty,almatyCity
Restoration,byDevelopmentOfHybridomaTechnologyHaveProducedInManyLaboratories
Other,Fbxo22
Other,decades
Other,possibility
Other,Management
Signature,subtype-specificSignature
Other,it
Chinese,chineseExpertGroup
Pathologic,pathologicalResults
Other,845Percecnt
Other,targetingFxyd3-mediatedPathway
Other,localRecurrence
Benchmark,reducedBaselineLvef
Other,significantlyUp-regulated
Caregiver,sufferingFromWoman'sDisease
Considerable,otherSignificantConcerns
HER2,foundBetweenMolecularSubtypesWithHer2
Other,examined
Other,mostPowerfulTool
Hybrid,oneMutation
Intensity,massMedia
Other,haveBackbone
Other,Applications
Other,thirdInTermsOfSpecificMortality
Techniques,severalIntelligentTechniques
Pathologic,pathologicalSpecimen
Intensity,tumorSize
Accumulation,survivalData
Township,shanxiProvinceOfChina
Intensity,highCorrelation
Sensitive,alive
Other,lungMetastasesFromBreastCancerPresented
Contribution,ccsCoverage
Other,theirPotentialClinicalImplicationsOnBreastCancer
Distance,firstTimeIn1984
Entry,induction
Other,identified
Focus,two-yearStudy
Symptom,effectOfDscam-as1
Other,presence
Contribution,analysisMayAid
Cell,canStartedAtVeryEarlyStage
Restoration,care
Intensity,higherProportionOfPatientsWithLymphedema
Other,rapidBreast-cancer-tissueDiagnosis
Other,up-regulated
Other,fused
Other,haMoietyForPdt
Other,commonCancer
OS,osAdvantage
Restoration,maintenanceOfErCancerStemCells
Other,flankingCgi
Other,insights
Distance,firstDataOnPre-diagnosisConcentrationsOfSrankl
Hazard,lowerCumulativeHazardRates
Other,tnmStage
Other,respectivelyFound
Danger,estrogenicExposure
Axis,pdgfs/pdgfrsAxis
Other,management
Other,Belgium
Box,transcriptionFactorForkheadBoxC1
Conflict,difference
Considerable,significantCausativeGenes
Other,therebyFrequentlyNeglected
Testing,medicalHistory
Other,procedure
Danger,mostProminentCause
Other,variousEnvironments
Other,functions
16,knowledgeOfM
Isolation,regression
Other,staging
Coefficient,weight
Genes,genesInvolved
Other,related
Radiotherapy,chemotherapyHormonalTreatment
Other,Probes
Other,aspects
Other,reported
Benchmark,benchmarkMethod
Benchmark,reducedBaselineCardiacFunction
Utilized,areUsed
Other,furtherStudies
Weight,whole-tumorSamplingOfDiseaseBurden
Adulthood,195Years
Food,mtorInhibitorEverolimus
Factors,adjustingForPotentiallyConfoundingFactors
Numerous,manyComputerVisionApplications
Contribution,present
Disease,malignantPleuralEffusion
Other,completionOfReproductivePlans
Other,stable
Focus,muchFocus
Other,evaluated
Intensity,highIndex
Other,oncogenes
Ecchymosis,nf-krab-inducedIncreasedExpressionOfCcnd1
Odds,speed
Sites,averageOfFiveInvolvedSites
Positivity,receiverOperatingCharacteristicCurves
Actual,oxidationPeakCurrent